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ABSTRACT
The physical tumor microenvironment contributes significantly to carcinogenesis, cancer
progression and metastatic dissemination. Two main components of the tumor
microenvironment, hypoxia and acidosis, are present in nearly every solid tumor and act as
powerful selection forces against the tumor. Hypoxia and acidosis promote tumor heterogeneity
and contribute to chemotherapy and radiotherapy resistance. This dissertation interrogates
methods to target the tumor microenvironment including two novel studies describing
mechanisms of buffer therapy resistance and targeting tumor hypoxia with vasodilators to
enhance the efficacy of a hypoxia activated prodrug, TH-302.
In the first study, mechanisms of buffer therapy resistance were identified and detailed.
Many studies have shown that the acidity of solid tumors contributes to local invasion and
metastasis. Oral pH buffers can specifically neutralize the acidic pH of tumors and reduce the
incidence of local invasion and metastatic formation in multiple murine models. However, this
effect is not universal as we have previously observed that metastasis is not inhibited by buffers
in some tumor models, regardless of the buffer used. B16-F10 (murine melanoma), LL/2
(murine lung) and HCT116 (human colon) tumors are resistant to treatment with lysine buffer
therapy, whereas metastasis is potently inhibited by lysine buffers in MDA-MB-231 (human
breast) and PC3M (human prostate) tumors. In the current work, I confirmed that sensitive cells
utilized a pH-dependent mechanism for successful metastasis supported by a highly glycolytic
phenotype that acidifies the local tumor microenvironment resulting in morphological changes.
In contrast, buffer-resistant cell lines exhibited a pH-independent metastatic mechanism
vii

involving constitutive secretion of matrix degrading proteases without elevated glycolysis.
These results have identified two distinct mechanisms of experimental metastasis, one of which
is pH-dependent (buffer therapy sensitive cells) and one which is pH-independent (buffer therapy
resistant cells). Further characterization of these models has potential for therapeutic benefit.
In the second study, improving the efficacy of hypoxia activated prodrug, TH-302,
through induction of hypoxia was investigated. Pancreatic ductal adenocarcinomas are
desmoplastic and hypoxic tumors, both of which are associated with poor prognosis. Hypoxia
activated prodrugs, such as TH-302, are specifically activated in hypoxic environments and are
now in a Phase III clinical trial in pancreatic cancer. Using animal models, we show that tumor
hypoxia can be exacerbated using a vasodilator, hydralazine, improving TH-302 efficacy.
Hydralazine reduces tumor blood flow through the “Steal” phenomenon, where atonal immature
tumor vasculature fails to dilate in coordination with normal vasculature. The current study
shows that MiaPaCa-2 tumors exhibit a “Steal” effect in response to hydralazine, resulting in
decreased tumor blood flow and subsequent tumor pH reduction. The effect is not observed in
SU.86.86 tumors with mature tumor vasculature, as measured by CD31 and smooth muscle actin
(SMA) immunohistochemistry staining. Combination therapy of hydralazine and TH-302
resulted in a reduction in MiaPaCa-2 tumor volume growth after 18 days of treatment. Further
optimization of hypoxia-inducing agents and dosing regimens may lead to increased TH-302
activity, potentially improving clinical outcome.
The data presented here demonstrate methods to effectively target the tumor
microenvironment for therapeutic benefit. Further investigation into mechanisms of action and
biomarkers for therapy response may have important implications on clinical treatment regimens
for cancer patients.
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CHAPTER 1
INTRODUCTION

Cancer
The word “cancer” is quite deceiving as it implies cancer is a single disease. However,
with increasing technological advances, we now know that “cancer” represents hundreds of
different diseases. Even seemingly more specific types of cancer, such as breast cancer and lung
cancer, are actually are made up of many cancer subtypes. Cancer is an extremely
heterogeneous disease, characterized by unregulated cell proliferation in a malignant lesion.
Cancer was first described in 3000 B.C. in Egypt in the Edwin Smith surgical papyrus [1] and
has been studied in great detail since then. Toxic chemicals have historically been used to kill
cancer cells, often with great sacrifice to the patient’s health [2]. Upon the advent of molecular
biology, cancer research focused heavily on cancer genetics and the abundance of molecular
mutations that are found in tumors, spurring the birth of targeted therapies. Common mutations
were identified that transform normal cells and promote malignancy, known as oncogenes.
Targeted therapies, such as EGFR inhibitors in lung cancers [3], HER2 inhibitors in breast
cancer [4], or B-raf inhibitors in melanoma [5], target the most prevalent oncogenes and are
often efficacious initially. Each targeted therapy, however, ultimately succumbs to resistance
and becomes ineffective. Resistance to targeted therapies can be innate or emerge from newly
acquired mutations that occur following exposure to chemotherapy.
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The emergence of resistant populations in response to chemotherapy is due in large part
to tumor heterogeneity. Tumors are known to be extremely heterogeneous and contain regions
of distinct genetic and phenotypic subpopulations. Bert Vogelstein, among others, has
documented the heterogeneity of a tumor extensively. By studying regional heterogeneity in
colorectal tumors, he proposed a model of cancer progression detailing mutations that were
acquired one by one over time [6-9]. Similarly, Gerlinger and colleagues identified regionally
distinct subpopulations of cells within renal cell carcinoma tumors [10]. Each region of tumor
was analyzed using deep sequences methods to identify genetic mutations that were maintained
throughout the tumor, as well as genetic mutations that were unique to each population.
Regional differences in the mutation load were used to model the evolution of tumor
development and identify regions which ultimately metastasized to distant sites. Genetic
alterations found in tumors can occur from germline mutations, environmental carcinogens or
chronic inflammation, and are thought to occur over a period of years or even decades.
Tumor heterogeneity remains the biggest obstacle for targeted therapies. Targeted
therapies, by design, are effective only towards tumor cells harboring a specific mutation,
leaving portions of the tumor unaffected. Additionally, when administering cytotoxic targeted
therapies to cancer patients, we are unintentionally applying a powerful selection force upon the
tumor. Genetic instability (a hallmark of cancers) facilitates a mutator phenotype, increasing
tumor heterogeneity in response to stresses, including cytotoxic therapy [11]. Resistant
populations eventually emerge from heterogeneous tumors, rendering the targeted therapy
ineffective [12]. Approaching cancer therapy from an evolutionary perspective and using
methods like adaptive therapy may prove to be a more efficient way to use targeted therapies
clinically while controlling the emergence of resistant populations [13,14].
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The Tumor Microenvironment
Tumors consist of much more than a population of cancer cells. The tumor
microenvironment encompasses the region of the tumor and everything it contains, including
various cell types, such as cancer-associated fibroblasts and immune cells, and the physical
features of a tumor, such as hypoxia and acidosis. The tumor microenvironment is often
overlooked when designing and using targeted therapies to treat patients despite the fact that it
contributes significantly to tumor progression, malignancy, and therapy resistance. The physical
characteristics of the tumor microenvironment have been studied in great detail, and unlike the
variability of genetic mutations that are found in tumors, hypoxia and acidosis are present in
nearly every solid tumor, making them an ideal target for therapy [15-19].
While present in nearly every solid tumor, acidosis and hypoxia can vary regionally
within a tumor. Hypoxia can be spatially and temporally heterogeneous and contributes
significantly to tumor progression and malignancy. Diffusion-limiting hypoxia results when the
diffusion limitation of oxygen (~200 µm) prevents oxygenation of tumor tissue at greater
distances from tumor vasculature. Perfusion limitations result from immature and chaotic tumor
vasculature and cause temporal changes in tumor perfusion [20]. Hypoxia, especially
intermittent hypoxia, induces extreme genotoxic stress and enables genetic mutations to occur
through repression of DNA damage repair pathways [21]. Tumor hypoxia is a negative
prognostic indicator and a strong predictor of metastatic potential [22]. Hypoxic tumors are also
less responsive to chemotherapy and radiotherapy treatment, contributing to resistance [22].
Tumor hypoxia also promotes changes in tumor metabolism by increasing anaerobic
glycolysis as an alternative way to breakdown glucose in the absence of oxygen. Overtime,
upregulated glycolysis becomes a fixed phenotype and occurs even in the presence of oxygen.
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This phenomenon was first characterized in the 1920’s by Otto Warburg and has since been
termed the Warburg Effect [23]. Acidosis quickly results in tumors due to increased excretion of
lactic acid, a byproduct of aerobic glycolysis, and the inability of the tumor vasculature system to
remove lactic acid waste. Tumor acidosis is clastogenic, resulting in genetic instability through
induction of chromosome breaks and translocations [24]. The presence of tumor acidosis
reduces drug efficacy through protonation of weak base chemotherapies, contributes to
chemoresistance, and increases the metastatic potential of cancer cells [25,26].
Carcinogenesis and the Tumor Microenvironment
The tumor microenvironment plays a critical role in carcinogenesis. Gatenby and Gillies
have proposed a model of carcinogenesis in which tumor adaption occurs in response to
microenvironmental proliferation barriers that exert evolutionary selection forces on the cancer
cells [27]. They hypothesize that the common phenotypes of invasive cancers, the hallmarks of
cancer [28,29], arise from clones that exhibit increased fitness in response to selective pressures
from microenvironmental proliferation barriers. Initially, as tumor cells begin to grow away
from the basement membrane into a hyperplasic lesion, cells encounter the normal cellular
response of apoptosis. Phenotypes that allow tumor cells to remain insensitive to anti-growth
signals are selected for, often through resistance to anoikis and contact inhibition. Inadequate
growth promotion occurs when growth factors and serum become limiting as tumor cells move
away from the basement membrane. Self-sufficiency in growth signals is selected to increase the
fitness of the tumor cells, and is often achieved through up-regulation of growth factor signaling
pathways. As cells continue to grow and divide, entry into senescence becomes the next
microenvironmental proliferation barrier. Tumors most commonly overcome this through
upregulation of telomerase to select for limitless replicative potential. As cells continue to grow
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from the basement membrane, oxygen becomes a limiting factor and hypoxia results. Unable to
catabolically consume glucose substrates through the oxygen-dependent tricarboxylic acid cycle
(TCA), or oxidative phosphorylation (OXPHOS), clones that have increased glycolytic flux
become selected for and outgrow clones lacking mechanisms to support increased glycolysis.
Acidotic waste from upregulated glycolysis floods the tumor microenvironment and becomes
stagnant, due to chaotic and immature tumor vasculature, dropping the tumor pH significantly.
Acidoisis, which is toxic to normal cells selects for cells that are resistant to acid-mediated
toxicity. Finally, ischaemia becomes a microenvironmental proliferation barrier, which selects
for sustained angiogenesis as well as invasive and metastatic clones.
It is important to note that the order of the microenvironmental barriers are fluid and do
not need to occur in the order proposed. For example, entry of cell into senescence may occur
before cells detach from the basement membrane. The objective of the model is to consider
carcinogenesis from an evolution dynamics perspective. The tumor microenvironment is the
adaptive landscape that applies selective pressures upon tumor cells, and the fitness of clones to
the current microenvironmental selection pressure determines their outgrowth. This model also
supports a common observance of significant heterogeneity within a tumor, most likely due to
the outgrowth of numerous clones with the variable tumor microenvironment.
More recently, Gillies, Verduzco and Gatenby have proposed a unifying model of
carcinogenesis that further describes the evolutionary selection pressure exerted by the tumor
microenvironment upon a tumor [30,31]. In addition to increasing genomic instability and
mutation load of a tumor, hypoxia and acidosis themselves are potent evolutionary selection
forces that alter the landscape of a tumor. Together, they increase the rate of evolution of a
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tumor and increase tumor heterogeneity, ultimately leading to increased malignancy and
resistance to therapy.
Manipulating the Tumor Microenvironment for Therapeutic Benefit
The presence of hypoxia and acidosis in virtually every tumor, along with their influence
on cancer progression and metastasis make them ideal targets for therapy. Manipulation of the
tumor microenvironment has the potential to prevent tumor progression, inhibit metastatic
disease and increase the efficacy of currently available targets. Developing therapies that target
cancer phenotypes, rather than genotypes, has significant advantages over conventional targeting
therapies.
The risk of developing resistance is reduced when targeting phenotypes rather than
genotypes. Convergent evolution occurs frequently in tumors, and genetic instability and
heterogeneity increases the chances that cancer cells will select for mutations that overcome
inhibition by chemotherapy [32]. This is evident in the number of mutations that are found in a
single cell signaling pathway. For example, self-sufficiency in growth signals is a common
phenotype of cancers and is a hallmark of cancer [28,29]. The number of mutations that have
been identified that can lead to self-sufficiency in growth signals is astronomical. Mutations can
occur in the receptor tyrosine kinase themselves, either in the extracellular domain or the
intracellular signaling domain, leading to constitutive pathway activation. Downstream signaling
proteins can also be mutated to constitutively activate a cell growth pathway, negating the need
for the receptor tyrosine kinase. Inhibition of one portion of a cellular signaling pathway will
ultimately lead to mutations in other portions of the pathway. This has been observed clinically
in patients treated with erlotinib, an inhibitor of EGFR [3]. Despite initial response to treatment,
patients eventually develop resistance to erlotinib and become unresponsive to treatment. To
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date, 12 mechanisms of resistance to erlotinib have been identified, confirming the complexity of
targeting cancer genotypes [33].
Targeting cancer phenotypes will be efficacious on larger populations of patients, instead
subpopulations of patients harboring a single genetic mutation. Targeting the tumor
microenvironment is an ideal therapeutic approach. Phenotypes such as tumor hypoxia and
acidosis are commonly found in solid tumors and contribute significantly to cancer progression
and malignancy. This dissertation will describe current therapies that are being investigated
preclinically and clinically to inhibit the two main physical features of the tumor
microenvironment: hypoxia and acidosis. Additionally I will describe two aspects of my
doctoral work focused on manipulating the tumor microenvironment for therapeutic benefit: 1)
Identifying mechanisms of buffer therapy resistance, and 2) Manipulating tumor hypoxia to
increase the efficacy of hypoxia activated prodrugs in pancreatic tumors.
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CHAPTER 2
MANIPULATING THE TUMOR MICROENVIRONMENT FOR
THERAPEUTIC BENEFIT

Note to Reader
Portions of this chapter have been previously published in Advances in Pharmacology,
2012, 65:63-107 [34], and are utilized with permission of the publisher.

Introduction
In chapter 1, I introduced a microenvironmental model of carcinogenesis [27,35]. Two of
the microenvironmental characteristics, tumor hypoxia and acidosis have been studied
extensively to elucidate their role in tumor initiation and progression (described in detail below).
As hypoxia and acidosis are present in virtually all human solid tumors, targeting these two
phenotypes, the “causes and consequences” of the tumor microenvironment, is an effective way
to reach a large population of patients to overcome tumor growth and metastasis. In this chapter,
I describe developmental drugs to target various aspects of hypoxia, cellular response to hypoxia
and tumor metabolism. Finally, I detail methods that are currently being investigated
preclinically and clinically to manipulate the tumor microenvironment for therapeutic benefit.
Targeting Hypoxia in the Tumor Microenvironment
Hypoxia is a common phenotype of solid tumors. As tumors grow, proangiogenic factors
stimulate new vessel growth within a tumor. However, these new vessels tend to be immature
8

and chaotic, and hence lead to poor perfusion [36]. Tumors found to contain hypoxic regions
typically respond poorly to therapy in the clinic [20]. Hypoxia can be difficult to target due to its
spatial and temporal heterogeneity within tumors and the fact that hypoxic volumes are the most
poorly perfused. Nonetheless, successful approaches to target hypoxia have been developed, and
some of these are in clinical trials. These approaches can be broadly described as (1) targeting
hypoxia response pathways; (2) drugs that require hypoxia for their activity and thus efficacy and
(3) methods to manipulate hypoxia to our advantage to increase efficacy of hypoxia-activated
prodrugs (Table 2.1).
Table 2.1 Drugs Targeting Hypoxia or Hypoxia Response Pathways
Drug
Target
Stage of Development
Topotecan
Topo I/HIF1α expression
FDA approved (ovarian,
cervical, SCLC)
EZN-2968
HIF1α expression
Phase I/Pilot study
PX-478
HIF1α expression/protein
Phase I
stability
Rapamycin
mTOR
FDA approved for nononcogenic indications
CCI779 (temsirolimus)
mTOR
FDA approved (renal cell
carcinoma, mantle cell
lymphoma)
RAD001(everolimus)
mTOR
FDA approved (renal cell
carcinoma, pancreatic
neuroendocrine tumors & nononcogenic indications)
Metformin
AMPK/mTOR/cell cycle
FDA approved for nononcogenic indications
Bortezomib (PS-341)
Proteosome/UPR
FDA approved (mantle cell
lymphoma, multiple
myeloma)
STF-083010
IRE1/UPR
Preclinical
Salicaldehydes
IRE/UPR
Preclinical
Tirapazamine (TPZ)
Hypoxia
Clinical trials completed
TH-302
Hypoxia
Phase I-III
Banoxantrone (AQ4N)
Hypoxia
Phase I
Apaziquone (E09)
Hypoxia
Phase I-III
PR-104
Hypoxia
Phase I-II
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Targeting Hypoxia Response Pathways
Tumors typically have lower oxygen concentrations (pO2) than levels detected in normal
tissue [37]. As a tumor grows outward, away from blood vessels, the ability to receive oxygen
from diffusion through tissue diminishes quickly leading to diffusion-limited (or chronic)
hypoxia. Additionally, perfusion-limited (or acute) hypoxia can result from variable blood flow
through chaotic and immature vessels that are characteristic of tumors. Hypoxia can be a
significant source of stress for cancer cells and several survival and response pathways have been
identified that allows cancer cells to overcome oxygen stress.
Targeting the HIF1α Pathway
Modulation of the hypoxia response in cells is orchestrated by transcription factors,
hypoxia inducible transcription factors, HIF1α and/or HIF2α. Under normoxic conditions,
HIF1α is inactivated via proteasomal degradation, regulated by the VHL ubiquitin ligase [38,39].
In response to hypoxia, HIF1α is not degraded and the resulting stabilized protein will
heterodimerize with HIF1β (a.k.a. the aryl hydrocarbon receptor nuclear translocator, ARNT)
and activate promoters containing hypoxia response elements (HREs). Transcriptional targets of
HIF1α can be found in glycolytic, angiogenic, survival, and migration pathways [40].
Constitutive HIF1α stabilization has been observed in many cancers and is correlated with
aggressive disease, poor prognosis, and drug resistance, making HIF1α an attractive drug target
[41-44]. This is an active area of research and there are numerous investigational drugs aimed at
inhibiting HIF1α with a number of approaches: for example, targeting HIF1α mRNA expression,
protein translation, protein stability, and transcriptional activity. Following, we illustrate some
of these approaches. More exhaustive discussion of this subject can be found at [45]. Topotecan
is an FDA approved drug that is indicated for ovarian, cervical cancers, and small cell lung
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carcinoma. The primary mechanism of action is through inhibition of topoisomerase I which
induces genotoxic stress through DNA double strand breaks [46]. Screening of the NCI
Diversity Set of chemical compounds for small molecule inhibitors led to the discovery of a
second mechanism of topotecan activity through inhibition of HIF1α expression [47]. Further
topotecan studies confirmed inhibition of HIF1α expression, concluding that translation of
HIF1α is inhibited in a topoisomerase 1-dependent mechanism by topotecan [48]. Tumor
xenograft models treated with topotecan have decreased HIF1α levels, diminished angiogenesis,
and reduced tumor growth [49]. Furthermore, patients treated with topotecan had low to
undetectable levels of HIFα in tumor biopsies, correlating with decreased levels of vascular
endothelial growth factor (VEGF) and GLUT1 [50]. Seven of 10 patients treated with topotecan
to receive dynamic contrast enhanced (DCE)-MRI exhibited decreased blood flow and
permeability through their tumors after one treatment.
Abolishing expression of HIF1α has been shown to be an effective way to inhibit tumor
growth, inspiring the development of methods to target mRNA expression of HIF1α as an
alternative to targeting HIF1α stability. An antisense oligonucleotide designed to inhibit HIF1α
expression has moved into clinical trials [51]. EZN-2968 was developed by Enzon
Pharmaceuticals, Inc. using locked nucleic acid (LNA) oligonucleotide technology to reduce
HIF1α expression [52,53]. EZN-2968 was confirmed to selectively inhibit HIF1α mRNA
expression in vitro, resulting in a lasting decrease in HIF1α protein levels, followed by a
reduction in expression of HIF1α target genes. EZN-2968 also showed activity in a tumor
xenograft model by repressing tumor growth. Phase 1 clinical studies treating hematologic
patients with EZN-2968 have recently concluded (NCT00466583) and have been followed by a
pilot trial that is currently recruiting patients with liver metastasis (NCT01120288).
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PX-478 is an orally available small molecule that has been shown to inhibit HIF1α
activity by reducing HIF1α levels [54]. Tumor xenograft experiments using a variety of tumor
cell lines showed that treatment with PX-478 reduced tumor growth or tumor regression which
correlated with decreased levels of HIF1α and its target genes GLUT1 and VEGF. The half-life
of PX-478 in murine plasma is short at 50 min, although concentrations capable of inhibiting
HIF1α expression can be found for 8 h. Imaging of tumor xenografts with DCE and diffusionweighted (DW)-MRI showed that treatment with PX-478 reduced tumor blood vessel
permeability within 2 h of treatment and returned to normal 48 h after treatment [55].
Mechanistic studies have revealed that PX-478 may have multiple mechanisms of action in the
inhibition of HIF1α by hindering both transcription and stability of HIF1α protein [56]. PX-478
can also contribute to clinical efficacy by acting as a radiosensitizer in prostate cancer cell lines
and in in vivo tumor models [57,58]. Recently, phase I clinical trials investigating the safety and
preliminary efficacy of PX-478 in patients with advanced solid tumor or lymphomas were
completed (NCT00522652). Results from the phase I trial, presented at the 2010 ASCO Annual
meeting, showed stable disease (SD) in ~40% of participants with mild toxicities [59].
Targeting mTOR
The mammalian target of rapamycin (mTOR) is a kinase that is activated during cell
stresses, including nutrient and energy depletion, triggering a signaling cascade regulating
metabolism and many cell survival mechanisms [60,61]. mTORC1, a subunit of a complex
nucleated by mTOR, has been shown to be important for tumorigenesis following activation of
AKT [62]. Exposure to hypoxia in normal cells promotes activation of the tuberous sclerosis
protein 1 complex (TSC1/2), which in turn negatively regulates the mTOR complex [63].
Additional evidence indicates that inhibition of the mTOR complex due to hypoxia can be
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accomplished through interaction with promyelocytic leukemia (PML) tumor suppressor or
disruption of mTORC1 binding to RHEB [64,65]. It is hypothesized that hypoxia mediated
inhibition of mTOR is a selective mechanism for mutations that are beneficial for cell growth in
hostile environments [66]. Alternatively, constitutively active mTOR has been observed in
advanced breast cancer. In addition, loss of mTOR repressors, such as PTEN and
TSC1/2, can result in unregulated mTOR activity [67,68]. While the exact role mTOR plays in
carcinogenesis is not fully understood, mTOR inhibitors have been successful on the bench, and
have moved into the clinic.
Rapamycin, a metabolite isolated from bacteria, was first identified in the 1970s to be a
powerful antifungal drug [69]. Rapamycin was quickly determined to have antitumor activity,
and was discovered to selectively target mTOR allosterically in the early 1990s [70,71].
Rapamycin also has potent immunosuppressive activity and is approved for transplant patients to
prevent organ rejection as well as anti-restenosis after heart surgery due to its anti-angiogenic
properties, but is not an approved medication for the treatment of cancer. Analogs of rapamycin,
or “rapalogs,” are constantly being designed to be more specific to mTOR and have better
pharmacologic properties and have been successful in the clinic. Currently, CCI779, or
temsirolimus, is approved for treatment of RCC and mantle cell lymphoma, and is being
investigated clinically for the treatment of other cancers, such as leukemia, non–small cell lung
cancer (NSCLC), and breast cancer [72-74]. RAD001, or everolimus, has been approved for
RCC and pancreatic neuroendocrine tumors, as well as an antirejection medication following
organ transplant [75,76]. In addition to single agent drugs, rapalogs are being investigated in
coordination with drugs that target other signaling pathways to improve efficacy, such as PI3K
or AKT [77-79].
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The antidiabetic drug metformin and its analogs buformin and phenformin have recently
been identified as having potential anticancer activity. Metformin reduces blood glucose levels
through decreasing hepatic gluconeogenesis and activation of AMPK (AMP-activated protein
kinase) and is commonly used clinically for the treatment of type 2 diabetes [80-82]. AMPK can
regulate activity of mTOR through activation of TSC1/2 [83]. Studies of diabetic patients
receiving metformin revealed significantly reduced cancer risk compared to cohorts receiving
other diabetic medications [84,85]. In vitro studies later confirmed that metformin represses
growth of breast cancer cells through an AMPK-dependent signaling and inhibition of mTOR
mechanism [86,87]. Metformin treatment seems to inhibit other cellular processes such as the
cell cycle through reduction of cyclin D1 and diminishing the transcription of GRP78, an
estrogen receptor chaperone protein that is elevated in cancers and involved in Unfolded Protein
Response (UPR) signaling [88,89]. Metformin is currently being investigated clinically to
determine if it is best used as a treatment or a preventative medication.
Targeting UPR
Hypoxia inhibits the ability of the endoplasmic reticulum (ER) to properly fold and
organize proteins. The UPR is activated in the ER under hypoxia stress, which functions to
maintain ER homeostasis or initiate apoptosis. Three proteins found at the ER membrane, PERK
(PKR-like ER kinase), IRE1 (inositol requiring 1), and ATF6 (activating transcription factor 6),
act independently to signal stresses leading to UPR activation [90]. Response by the UPR to
hypoxia is important for tumor growth, and aberrant UPR signaling due to the absence of PERK
or IRE1 results in increased regions of hypoxia and reduced growth rates [91,92]. Activation of
the UPR response results in both reduction of translation and inhibition of protein maturation
pathways as well as a detoxification process known as ER-associated degradation (ERAD) and
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induction of autophagy [93]. In addition to activation of UPR in response to hypoxia, other
cellular stresses often found in solid tumors can lead to UPR activation. Such stresses include
calcium homeostasis, redox status, and glucose depravation, making UPR an important cellular
response mechanism in cancer, and also an attractive pathway to target clinically.
The ERAD response to cellular stresses is activated by the UPR and results in priming
misfolded proteins to be shuttled out to the cytoplasm for proteasomal degradation [94].
Blocking the ERAD response through proteasome inhibitors like bortezomib (PS-341) has been a
successful strategy for tumors with high ER stress such as multiple myeloma [95,96]. Recent
research suggests that hypoxia sensitizes cells to ER stress resulting from bortezomib treatment,
leading authors to suggest pairing bortezomib with normoxia targeting drugs to improve
therapeutic response [97]. Such combinations have been investigated in murine models, and
have shown to repress tumor growth when bortezomib was used in coordination with a HDAC6
specific inhibitor, ACY-1215, in a multiple myeloma model [98]. Clinical trials are also
ongoing, investigating the efficacy of combining bortezomib treatment with other
chemotherapies, such as mitoxantrone (topoisomerase II inhibitor), mapatumumab (antibody
specific for TRAIL death receptor), and vorinostat (HDAC inhibitor).
IRE1 has two enzymatic domains, a kinase domain and an endonuclease domain
[99,100]. Crystal structures have shown that IRE1 dimerizes in a juxtaposed configuration that
allows for autophosphorylation resulting in increased endonuclease activity [101,102].
Screening for potential inhibitors of IRE1 using a cell-based reporter system identified STF083010 [103]. Treatment of multiple myeloma cells with ER stresses resulted in mRNA
cleavage of XBP1 by IRE1, which was abrogated with treatment of STF-083010 [104]. STF083010 was shown to selectively inhibit the endonuclease activity of IRE1 without affecting
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kinase activity. Although in vivo antitumorigenic responses were observed, more research will
need to be performed to optimize an IRE1 inhibitor using STF-083010 as a scaffold. Another
high-throughput screening search found salicylaldimine analogs to be inhibitors of IRE1 [105].
Similar to STF-083010, salicaldehydes inhibit IRE1 endonuclease activity in vitro and in vivo,
increasing the interest to develop more potent and selective inhibitors targeting IRE1.
Using Hypoxia to Our Advantage
Use of Bioreductive Drugs
Bioreductive prodrugs are a class of drugs that are inert in tissues with normal pO2 but
are able to undergo chemical reduction in tissues with severe hypoxia to release cytotoxic
warheads, selectively targeting cancer cells within hypoxic regions. In general, there are five
different chemical scaffolds that have been used to generate bioreductive prodrugs (nitro groups,
quinones, aromatic N-oxides, aliphatic N-oxides, and transition metals), all of which are able to
be reduced in the absence of oxygen. One of the earliest reports of the use of bioreductive
quinones to selectively target hypoxia is the use of mitomycin C in the 1960s [106,107]. During
the last half century, bioreductive drugs scaffolds have been improved upon making them more
selective and potent in hypoxic tumors.
Tirapazamine, or TPZ, is one of the most advanced bioreductive drugs through the
clinical trials process. TPZ is built off of an aromatic N-oxide bioreductive scaffold [108].
During hypoxia, TPZ undergoes an intracellular one-electron reduction to a radical anion, then
further converted to either a hydroxyl radical or an oxidizing radical, ultimately resulting in
DNA damage [109-111]. TPZ creates DNA interstrand cross-links which stall replication forks
and induce DNA breaks that require homologous recombination repair [112]. TPZ has been
extensively studied clinically in combination with cisplatin and radiation in patients with
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squamous cell carcinoma, head and neck cancer, and lung cancer with moderate to inconclusive
results [113-116]. Further analysis showed that TPZ was being metabolized too quickly, and
was not effectively penetrating tumor tissues [117,118]. Consequently, TPZ analogs are
currently being developed with the goal of improving drug solubility, cytotoxicity, selectivity,
and tissue penetration characteristics [119].
TH-302 is built upon a scaffold of a 2-nitroimidazole and is a nitrogen mustard prodrug
that is selectively reduced under hypoxia (<0.5% O2) [120]. As TH-302 is reduced, the prodrug
splits and releases its cytotoxic warhead, bromo-isophosphoramide mustard (Br-IPM). As BrIPM is released into hypoxic tissue, it cross-links with DNA, killing cells in the hypoxia
compartment as well as neighboring cells with its bystander effect [121,122]. TH-302 was shown
to have efficacy in vitro and in vivo in a wide subset of cancer cell lines and xenografts and was
further found to have favorable drug-like properties and pharmacokinetic profiles [120,123,124].
TH-302 entered phase I clinical trials as a single agent drug in patients with advanced solid
tumors and has also been tested in combination with doxorubicin in patients with advanced soft
tissue sarcoma, gemcitabine in patients with pancreatic cancer; docetaxel for patients with
prostate or lung cancers [125,126]. TH-302 was generally well tolerated, but some patients
experienced skin and mucosal dose-limiting toxicities. Recently, phase I/II clinical trials of TH302 as a single agent concluded with SD or better detected across a number of cancer types.
Current clinical trials are investigating the efficacy of TH-302 as a single agent or in
combination therapy for cancers, including melanoma, multiple myeloma, RCC, pancreatic
carcinoma, and phase III trials have begun in patients with sarcoma. TH-302 is more thoroughly
described in Chapter 4 of this dissertation.
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Banoxantrone, or AQ4N, is an N-oxide bioreductive prodrug that was developed to
selectively target hypoxic regions of tumors [127]. The reduction under hypoxia releases a
cytotoxic alkylaminoanthraquinone metabolite (AQ4) which induces DNA damage through
inhibition of topoisomerase II. AQ4N has been shown to be efficacious in murine models of
breast cancer when combined with chemotherapy or radiation therapy [128-130]. Phase I
clinical trials have investigated the activity of AQ4N either as a single agent or in combination
with radiation therapy [131,132]. AQ4N was well tolerated by patients and is now being tested
in clinical trials to evaluate the efficacy of AQ4N (NCT00394628, NCT00109356, and
NCT00090727).
Two other bioreductive drugs, apaziquone (E09) and PR-104, have been successful on
the bench top and have moved into clinical studies [133,134]. While bioreductive drugs have
been especially successful in preclinical studies, and have shown some success in the clinic, no
bioreductive prodrug has been approved by the FDA to date. Current research is aimed at
improving bioreductive prodrug selectivity, stability, and cytotoxicity. Additionally, research is
ongoing to develop bioreductive prodrugs that are non-genotoxic and instead target other cellular
processes. For example, 2-nitroimidazole-5-ylmethyl is a 2-nitroimidazole that releases 5bromoisoquinoline after reduction, targeting poly(ADP-ribose) polymerase 1 (PARP1) [135].
Manipulating Hypoxia
While the data from hypoxia activated prodrugs (HAPs) in the clinic are promising, it can
be reasoned that they may be more efficacious if tumor hypoxia can be selectively and
transiently increased at the time of treatment. Thus, inducing hypoxia in tumors can be an
efficient way of increasing the efficacy of drugs that target hypoxia. There are a number of
mechanisms available with which to exacerbate tumor hypoxia selectively, including
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metabolically (e.g., pyruvate or DCA), or by reducing oxygen delivery (e.g., antiangiogenic
agents or vasodilators).
It has recently been shown that tumor hypoxia can be increased following intravenous
injection of pyruvate [136,137], who’s mechanism of action may involve inducing cells to
increase respiration [137]. EPRI, a spectroscopic imaging technique that measures in vivo
oxygen concentrations, of tumors in mice following an intravenous injection of hyperpolarized
13C pyruvate revealed a significant decrease in tumor oxygenation that reached a maximum at 1
h, and returned to normal within 5 h [136]. Knowledge of a tumors oxygenation status is
important for treatment plans, as pyruvate-induced hypoxia reduced the ability of radiotherapy to
kill cancer cells even after tumor oxygenation had returned to normal levels. DCA, an inhibitor
of PDK, has also been reported to initiate a metabolic switch in cancer cells from glycolysis to
oxidative phosphorylation [138]. Induction of oxidative phosphorylation by DCA increased
reactive oxygen species, pH, and apoptotic proteins in HeLa cells. Additionally, the metabolic
switch observed after DCA treatment correlated with an increased sensitivity of HeLa cells to
cisplatin, suggesting that manipulation of a tumors metabolism may be therapeutically
successful.
Tumor oxygenation can also be manipulated by controlling oxygen delivery with
antiangiogenic or antivascular agents. Angiogenesis is a common phenotype (“Hallmark”) of
cancer that is regulated by HIF1a signaling [29]. Tumors support an induction of angiogenesis
by producing angiogenic growth factors such as VEGF and platelet-derived growth factor
(PDGF). Several antiangiogenic inhibitors that target the immature angiogenic vasculature have
been approved, including sorafenib, a VEGFR and PDGFR inhibitor, avastin (bevacizumab), an
antibody targeting VEGF, and sunitinib, a VEGFR and PDGFR inhibitor [139]. Although
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resistance to antiangiogenic drugs has become a major obstacle in clinical cancer treatment
[140], their use to acutely increase hypoxia in combination with HAPs has not yet been
published. Alternatively, there are agents, such as combretastatin, that will target mature vessels,
and these are also known to increase tumor hypoxia [141]. Another characteristic of the
immature tumor vasculature is a lack of tone. Thus, vasodilators, such as hydralazine, induce a
systemic drop in blood pressure, which is not matched by the tumor vasculature, causing a
transient decrease in perfusion within the tumor [142]. This “steal” phenomenon has been
demonstrated using Doppler Ultrasound to measure decreased tumor blood flow [143]. The
decrease in perfusion leads to increases in acidosis and hypoxia; both have been shown using pH
electrodes or MRS, for acidosis and pO2 electrodes for hypoxia [144-147].
Targeting Glucose Metabolism
Aerobic glycolysis has long been known to be a common hallmark of solid tumors. This
metabolic switch has been proposed to provide an advantage to growing tumors by allowing
adaptation to low oxygen environments. This leads to increased acidification of the local tumor
microenvironment, allowing for evasion of the immune system and increased metastatic potential
[35,148]. In the next section, we describe drugs that are in preclinical or clinical studies that
target glucose metabolism of tumors (Figure 2.1).
Targeting Glucose Transporters
Glucose, a major carbon source for cells, is a 6-carbon ring structure converted to
pyruvate canonically along the Embden-Meyerhof glycolytic pathway. Entry of glucose into
cells occurs by facilitated diffusion through a family of 14 membrane-bound proteins called
glucose transporters (GLUTs). GLUT1, the founding member of the GLUT family, was isolated
from erythrocytes in 1977 [149]. Upregulation of GLUT1 and GLUT3 expression has been
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Figure 2.1. Inhibitors of the Glycolytic Pathway. The figure depicts the glycolytic pathway
from glucose entry into cells through production of pyruvate, which is converted either to lactate
or to acetyl coA for entry into the TCA cycle. Movement of metabolic intermediates through the
pathway is designated by arrows. Enzymes in the glycolytic pathway are placed next to the
arrow leading from their substrate to their product. Inhibitors of glycolytic enzymes or glucose
transporters appear in boxes.

described in many cancers, and may be a key step in tumor progression. Increased expression of
GLUTs correlate with poor prognosis and short survival of patients with ovarian, breast, and
squamous cell carcinomas [150-152]. GLUT1 (Km = 6.9 mM) and GLUT3 (Km = 1.8 mM) each
have a high affinity for glucose, and are thought to be the main transport mechanisms for glucose
into cells [153-155]. Importantly, Hatanaka showed in 1974 that glucose uptake by cells is a
rate-limiting step in glycolysis. Subsequent work by other groups determined that transformed
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cells with increased expression of GLUTs at the plasma membrane is a strong independent
prognostic indicator for FDG uptake and glucose consumption [156-159].
Increased expression of GLUT1 and GLUT3 during tumor progression allows for
unregulated metabolism of glucose, making it an intriguing therapeutic target. Recent research
described the cytotoxic and chemosensitizing properties of anti-GLUT1 antibodies in numerous
lung and breast cancer cell lines reconfirming the importance of glucose uptake for survival
[160]. Decades of research have resulted in the discovery of many other GLUT inhibitors,
including Cytochalasin B and select tyrosine kinase inhibitors [161,162].
High-throughput screening for drugs capable of sensitizing cells that evade FAS ligandinduced apoptosis have identified fasentin, a small molecule inhibitor that binds to the
intracellular channel of GLUT1, reducing glucose transport [163]. Further studies uncovered
altered expression of genes involved in glucose metabolism following treatment of FAS-resistant
prostate and leukemia cells with fasentin and FAS ligand [164]. Ultimately, fasentin alone was
unable to induce cell death in FAS-ligand resistant cells, despite a rapid, albeit, partial reduction
in glucose uptake following fasentin treatment.
Renal cell carcinoma (RCC), known for harboring inactivating mutations in the von
Hippel-Lindau (VHL) ubiquitin ligase gene, was identified as a candidate for chemical synthetic
lethality screening for GLUT inhibitors [165]. VHL mutations often coincide with a reorganized
metabolic profile, wherein the tumor becomes highly glycolytic and relies on high levels of
GLUT1 expression. One class of compounds, led by STF-31, caused necrotic cell death in RCC
cells lacking functional VHL. In silico modeling revealed a potential docking site for STF-31
located in the central channel of GLUT1, and further functional studies confirmed inhibition of
GLUT1 by STF-31. FDG-PET scans confirm reduced glucose uptake in RCC tumors treated
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with STF-31, corresponding with retarded tumor growth. Lack of toxicities resulting from
treatment with STF-31 encourages further research into its therapeutic potential and widespread
efficacy in other tumors overexpressing GLUT1.
Targeting Hexokinase
As glucose enters the cystol, hexokinase phosphorylates the sixth carbon, effectively
trapping glucose intracellularly and priming it for catabolism. Hexokinase-2 is frequently
overexpressed in cancers, overcoming silencing methylation found on its promoter in normal
tissues [166]. Expression of hexokinase is transcriptionally regulated by both p53 and hypoxiainducible factor 1a (HIF1α) [167]. Glucose analogs, specifically 2-deoxyglucose, can be
radiolabeled to image tumors with increased glucose uptake (18FDG), and have also been studied
as inhibitors of glycolysis [168,169]. These analogs enter cells normally through GLUT1 or
GLUT3 transporters and are phosphorylated by hexokinase. As with glucose, the 6-phospho
form of these analogs are unable to exit cells, and are feedback inhibitors of hexokinase activity.
However, unlike glucose, the phosphorylated glucose analogs are unable to be rapidly
catabolized through the remainder of the glycolytic pathway, that is, phosphofructokinase, and
can build up to high levels intracellularly, where they prevent further glucose metabolism.
Although there have been some successes using deoxyglucose in vitro and in animal models as a
glycolytic inhibitor, clinical successes have not extended past utilization as an imaging contrast
agent to visualize tumors or as a radio-sensitizing agent [170,171].
3-bromopyruvate (3-BrPA) has been identified as a potent inhibitor of glycolysis through
its promiscuous inhibition of hexokinase-2 as well as glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). 3-BrPA has been widely studied as an alkylating agent, but its first
anticancer properties were identified in 2001 as an inhibitor of hexokinase-2 [172-174].
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Selectivity appears to depend on its uptake by overexpressed monocarboxylate transporter,
SLC5A8 [174]. In addition to its use as a single agent, recent research has focused on combining
3-BrPA with other chemotherapies to overcome ATP-requiring multidrug resistance (MDR)
mechanisms. Nakano et al. used 3-BrPA to sensitize MDR-expressing tumors to daunorubicin or
doxorubicin treatment [175]. Similar work by Zhou et al. confirms that intracellular ATP is
essential for drug resistance, and that disruption of cellular energy levels through inhibition of
hexokinase-2 by 3-BrPA resensitized MDR cells to therapy [176].
Lonidamine was first identified as an inhibitor of aerobic glycolysis through inhibition of
hexokinase-2 in tumor cells in 1981 [177,178]. As with 3-BrPA, inhibition of hexokinase-2 by
lonidamine induced apoptosis [179]. Lonidamine acts as a single agent and has been extensively
studied as a treatment for MDR [180,181]. Already approved for use as an anticancer
chemotherapy in Europe, phase II clinical trials began in the United States in 2005 treating
patients with benign prostatic hyperplasia (BPH) [179,182]. Despite reports of some cancer
patients receiving 40 times the dose than patients in the US trial, and indications that prostate
volumes were reduced during treatment, the US phase II trial was terminated due to liver
toxicities and no subsequent trials have begun [182,183]. In an effort to harness the therapeutic
efficacy of lonidamine against MDR and reduce toxicities due to dosage, Milane et al. have
developed epidermal growth factor receptor (EGFR)-targeted nanoparticles encapsulating
lonidamine and paclitaxel [183,184]. Orthotopic MDR-positive breast cancer xenografts treated
with targeted drug-containing nanoparticles showed reduced tumor growth compared to
treatment with blank nanoparticles. Transient weight losses were observed in all groups. Liver
toxicities were highest in animals treated with soluble paclitaxel alone or soluble paclitaxel +
lonidamine, and were less severe when drugs were bound to nanoparticles. Hematologic
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analyses also revealed reduced toxicity following treatment with drug combinations encapsulated
within nanoparticles. Overall, lonidamine is a promising hexokinase-2 inhibitor that may show
clinical benefit either alone or in combination with other chemotherapies.
Targeting Phosphofructokinases
Phosphofructokinase-1 (PFK-1) catalyzes the phosphorylation of fructose-6-phosphate to
fructose-1,6-bisphosphate in a rate-limiting step in the glycolytic pathway. Regulation of PFK-1
activity is reduced as a result of oncogene activation, such as Ras or Src, through elevated levels
of fructose-2,6-bisphosphate’s physiologic activator of PFK-1 [185,186]. Phosphofructokinase-2
(PFK-2), as well as the p53 target TIGAR, is a regulator of the steady-state level of intracellular
fructose-2,6-bisphosphate, and the PFKFB3 isozyme has been identified to be overexpressed in
leukemias and solid tumors [187-189]. Small molecule inhibitors targeting the substrate-binding
domain of PFKFB3 have been identified as antineoplastic agents [189]. In vitro inhibition of
recombinant PFKFB3 revealed 3PO (3-(3-Pyridinyl)-1-(4-Pyridinyl)-2-Propen-1-one) as a lead
compound that inhibits PFKFB3 but does not affect activity of PFK-1. 3PO was further shown
to inhibit normal cell cycling in several solid tumor and hematologic cell lines further inhibiting
tumor growth in xenograft models of lung, breast, and leukemia by suppression of glycolytic flux
[189].
To improve upon clinical limitations of 3PO, such as solubility and high preclinical
doses, Akter et al. has engineered nanoparticle drug delivery systems for 3PO [190].
Encapsulating 3PO within a hydrophilic shell through conjugation to block copolymers
improved 3PO bioavailability. 3PO conjugated block copolymers were also engineered with a
hydrazone bond that is cleaved in acidic conditions (pH < 7.0) to preferentially target acidic
tumor microenvironments. In vitro experiments with 3PO containing micelles resulted in
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significant cell death across several cell lines providing encouragement for future work in
preclinical models.
In a separate study, N4A and YN1 were identified to be competitive inhibitors of
PFKFB3 [191]. While treatment of cells with these novel compounds resulted in decreased
glycolytic flux followed by cell death, selectivity of the drugs was not ideal, and further
optimization of the drug scaffold is currently underway.
Targeting Pyruvate Kinase M2
Pyruvate kinase (PK) catalyzes the transfer of a phosphate from phosphoenolpyruvate to
ADP in the final step of aerobic glycolysis, resulting in one molecule each of ATP and pyruvate.
Of the four pyruvate kinase isoforms, PKM1 is expressed in most tissues. PKM2 is a splice
variant of PKM1 that is primarily expressed in embryonic development, but is also reported to be
the main isoform expressed in tumors [192]. PKM2 expression has been associated with the
Warburg Effect, carcinogenesis, and tumor growth. Due to increased expression of PKM2,
cancer patients typically have higher levels of PKM2 in plasma and saliva, and this is being
investigated in a clinical trial to determine if salivary levels of PKM2 can be used as a biomarker
for malignancy (NCT01130584).
TT-232 (TLN-232/CAP-232) is a somatostatin structural analog that has been shown to
significantly reduce tumor growth in murine models, and has entered clinical trials for refractory
metastatic RCC and melanoma (NCT00422786 and NCT00735332). TT-232 has
antiinflammatory effects through its interaction with somatostatin receptor 4 (SSTR4), a G
proteincoupled receptor, and antitumor effects mediated through its inhibition of PKM2
[193,194]. Unlike somatostatin, TT-232 is able to exhibit antitumor effects without the
antisecretory activity that is required for somatostatin’s efficacy in neuroendocrine tumors and
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pancreatitis [195]. In addition to inhibition of PKM2, treatment of cells with TT-232 inhibits
proliferation, induces cell cycle arrest, and initiates apoptosis [196,197]. Phase I clinical trials of
TT-232 were successfully completed without significant adverse events, allowing entry into
phase II trials.
Targeting Pyruvate Dehydrogenase Kinase
Following the conversion of phosphoenolpyruvate to pyruvate by PK, further oxidation
of pyruvate is enabled by mitochondrial pyruvate dehydrogenase (PDH), which catalyzes the
oxidative decarboxylation of pyruvate to acetyl-CoA, which can then enter the tricarboxylic acid
(TCA) cycle. PDH is negatively regulated at three serine phosphorylation sites by pyruvate
dehydrogenase kinase (PDK), which shifts glucose from oxidative to glycolytic metabolism
[198].
Dichloroacetate (DCA) has been used clinically over the past several decades for the
treatment of lactic acidosis and mitochondrial disorders [199]. DCA is an inexpensive, orally
available drug that targets PDK [200-202], and has recently been shown to have anticancer
effects both in vitro and in vivo [138,203]. The Michelakis group hypothesized that inhibition of
PDK with DCA could shift glucose metabolism from glycolytic to oxidative, eliminating
excessive lactic acid production observed in cancer cells [204]. Indeed, treatment of lung,
glioblastoma, and breast cancer cells reversed cell metabolism from glycolytic to oxidative; and
in doing so increased ROS production, decreased mitochondrial membrane potential, and
sensitized cells to apoptosis. In vivo rodent studies demonstrated the antitumor properties of
DCA by reducing overall tumor volumes and inducing apoptosis in a lung cancer xenograft
model [204]. Further preclinical studies have shown DCA to have similar proapoptotic effects
on endometrial cancer cells as well as sensitizing prostate cancer cells to radiation therapy
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[203,205]. Numerous clinical trials are currently recruiting, or underway, to administer DCA as
a single agent, or in combination with other chemotherapies or radiation, in a wide range of
cancers. The first published data from clinical trials with DCA as an anticancer therapy was
recently published [206]. Resected glioblastoma tissue from 49 patients treated with DCA
confirmed mitochondrial depolarization in vivo. Five patients with either newly diagnosed or
recurrent glioblastoma were placed on a treatment regimen of DCA with standard therapies,
temozolomide (TMZ) and radiation therapy, after surgical tumor debulking. During a 15-month
follow-up, toxicities were moderate, with peripheral neuropathy being the only toxicity noted
with ~80% of patients remaining clinically stable 15 month after the onset of therapy.
Targeting Lactate Dehydrogenase (LDH)
Lactate dehydrogenase (LDH) catalyzes the interconversion of pyruvate and lactate.
LDH is a tetrameric protein made from two different (heart and muscle) subunits. LDH5 (a.k.a.
LDH-A or M4) is usually expressed in muscle tissue and has a low Km for pyruvate, while LDH1
(a.k.a. H4) is more ubiquitously expressed and has a lower Km for lactate. During the redox
reaction of pyruvate to lactate, NADH is oxidized to NAD+, replenishing intracellular levels of
NAD+ and allowing glycolysis to become self-sufficient. LDH5 subunits are transcriptionally
regulated by HIF1α and hence levels of LDH5 are increased in HIF1α–positive cancers
[207,208]. Recently, LDH5 has been shown to be important for tumor initiation, although the
exact mechanism is currently unclear [209-211].
Gossypol, a cotton seed extract, has been studied as an antifertility drug that inhibits
sperm LDH, and further experimentation has revealed cross inhibition of gossypol analogs to
LDH5 [212]. More recent gossypol analog studies focusing on 8-deoxyhemigossylic derivatives
that target the NADH and pyruvate binding sites of LDH identified 3-dihydroxy-6-methyl-7--
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(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid, or FX11, as a preferential inhibitor of
LDH5 [213]. Treatment of human lymphoma cells, P493, with FX11 correlated with
knockdown of LDH5 by siRNA by increasing oxygen consumption, ROS production, decreasing
ATP levels, and cell death [214]. Similar results were observed in RCC and breast cell lines,
with the sensitivity to FX11 being highest in cells with a more glycolytic phenotype. In vivo
studies also indicated that FX11 inhibits both carcinogenesis and tumor progression of
lymphoma and pancreatic tumors [214]. It was notable that these treatments were not
myelosuppressive or toxic, despite the presence of LDH-A in normal tissues. Although a
promising candidate drug to target the glycolytic phenotype of tumors, FX11 is not yet in clinical
trials.
The most recent research for novel LDH5 inhibitors began in an attempt to fabricate a
drug suitable for entry into the clinic. From this research, a series of N-hydroxyindole-based
inhibitors were generated to have specificity for LDH5 over LDH1 [215]. In vitro experiments
showed promising Ki values in the low micromolar range for some of the compounds
synthesized. Additionally, cellular assays resulted in reduced lactate production and retarded
cellular proliferation. Virtual screening of the National Cancer Institute (NCI) Diversity Set by
another group identified galloflavin as a novel LDH inhibitor [212]. Galloflavin was further
characterized and shown to bind preferentially to free enzyme without blocking either the
pyruvate or NADH binding sites. Enzymatic assays using purified LDH1 and LDH5 showed
that galloflavin acts as an inhibitor of both isoforms. Cellular assays confirmed in vivo activity
of galloflavin with reduced lactate production, a reduction of cellular ATP levels, and decreased
cellular proliferation. Preliminary murine experiments suggest that galloflavin could be a welltolerated drug that should be developed further.
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Targeting Acidosis
The microenvironment of solid tumors is known to be more acidic (pH 6.5–6.9) than the
physiological pH of normal tissue (pH 7.2–7.5), which can be attributed to a tumor’s increased
glycolytic flux and poor vasculature perfusion [15,16]. Acidic microenvironments have been
shown to increase the invasiveness of a tumor, leading to increased metastasis [26,216,217]. In
this section, we will describe drugs that target acidosis in tumors and systematic approaches to
reduce acidosis in the tumor microenvironment (Figure 2.2).
Targeting Proton Transport
Metabolically produced hydrogen ions (acid) can be exported from cells by a variety of
mechanisms including, inter alia, sodium-hydrogen exchange (NHE), anion exchangers (AEs),
vacuolar ATPases (V-ATPases), and membrane-bound carbonic anhydrases (CAs) [218]. NHE
and AE are ubiquitously expressed and have proven to be poor anticancer drug targets, either
through inefficacy or through toxicity, and these have been reviewed [219]. Following, we will
discuss some of the newer, less well-explored members of this class of transporters. CAs are
metalloenzymes that catalyze the interconversion of carbon dioxide and water to bicarbonate and
protons. Mammalian carbonic anhydrases (α-CAs) can be cystolic, mitochondrial, secreted, or
membrane-bound. The primary function of mammalian CAs is to maintain the acid–base
balance of cells, tissue, and blood. As aerobic glycolysis becomes the primary means of energy
production for a tumor cell, the ability to regulate physiological pHi becomes paramount to
maintain cellular processes such as proliferation as well as inhibition of apoptosis [220,221].
CAIX and CAXII are two transmembrane CAs that have been identified to be associated with
tumor progression and metastasis [222-224]. As a transcriptional target of HIF1α, CAIX
expression is upregulated in hypoxic tissue and has been shown to be a poor prognostic marker
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Figure 2.2. Proteins that contribute to tumor acidosis and their inhibitors. The figure depicts
proteins and transporters that contribute to extracellular acidosis in a tumor due to increased
lactate production from increased glycolytic flux. Included are CAIX and CAXII, carbonic
anhydrases that catalyze the interconversion between carbon dioxide and water to bicarbonate
and protons; and V-ATPases and MCTs, which allow transport of H+ into the extracellular
environment. Inhibitors of the proteins that contribute to tumor acidosis appear in boxes.

in several cancer types, including breast cancer [225]. CAXII is also overexpressed in tumors
and is associated with disease progression and response to therapy [223,226]. As carbon dioxide
is hydrated, HCO3- is moved intracellularly to maintain pHi while protons are pumped into the
extracellular environment of a tumor, decreasing the pHe [226] promoting an aggressive
metastatic environment [227,228]. Members of α-CA require zinc for activity, making them
susceptible to inhibition by sulfonamides, which coordinates with the zinc ion found in the active
sites of CAs. Sulfonamide analogs, such as topiramate, sulpiride, and valdecoxib, have been
shown to potently inhibit CAXII, while zonisamide has been identified to be an effective
inhibitor of CAIX (Greenberger et al., 2008; Li et al., 2005). Perhaps the most studied
sulfonamide analog, indisulam, has high affinity for CAIX and CAXII, in addition to seven other
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CAs [229,230]. Indisulam inhibits CAIX in nanomolar quantities and shows efficacy against
tumor xenografts in vivo. In addition to CAIX inhibition, indisulam induced sequelae, such as
disruption of the G1/G2 phases of the cell cycle and expression changes of genes related to cell
adhesion, cell signaling, and altered glucose metabolism [231-233].
Clinical trials for the treatment of solid tumors with indisulam have been ongoing for the
past decade. Five phase I clinical trials have been conducted focusing on optimizing the dosing
regimen of indisulam to patients with solid tumors [234-238]. Fatigue and mucositis were noted
as adverse events during the trial, and reversible neutropenia and thrombocytopenia
were dose-limiting toxicities. Phase II trials have been completed on patients with platinumpretreated NSCLC in a multicenter study [239]. While some patients experienced a positive
response to indisulam, the effect was not long term. Objective responses to indisulam therapy
were not achieved during this trial, which may be attributed to inherent difficulties of being a
second-line therapy to platinum-pretreated NSCLC [240]. Further trials are being conducted
using indisulam as both a single agent and as combination therapy for different tumor types.
Another membrane-bound transporter involved with acidification of the tumor
microenvironment is V-ATPase [241,242]. In tumor cells, V-ATPases can prevent intracellular
acidification by transporting protons into lysosomal compartments that are released into
extracellular space, or by directly pumping protons into the tumor microenvironment [243]. In
addition to promoting tumor metastasis by acidifying the tumor microenvironment,
overexpression of V-ATPases following chemotherapy treatment appears to be a drug resistance
mechanism [244,245]. In 1988, bafilomycins were identified to be potent inhibitors of VATPases [246]. Since this discovery, several generations of V-ATPase inhibitors have been
developed and investigated and can be classified into five families of V-ATPase inhibitors [247].
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While targeting V-ATPases is desirable as an anticancer target to reduce metastatic potential and
drug resistance, clinical relevance is unknown due to likely toxicities [248-251].
The monocarboxylate transporter 1, MCT1, a membrane-bound transporter is required for
lactate (coupled with a proton) to move across the plasma membrane. MCT1 has been
documented to have dysregulated expression in colorectal, breast, and cervical carcinomas [252254]. Inhibition of MCT1 reduces intracellular pH and induces apoptosis, making it an attractive
target for antitumorigenic therapy [255]. Several small molecule inhibitors of MCT1 have been
identified including a-cyano-4-hydroxycinnamate (CHC), phloretin, and AR-C117977 [255,256].
Currently, no MCT1 inhibitors are being investigated clinically.
Manipulating Tumor Microenvironment pH
Orally distributed systemic buffers have been shown to be an effective way to increase
pHe of a tumor [257]. Continuous oral delivery of sodium bicarbonate to tumor bearing mice
have been shown to increase selectively the pHe of a tumor and are effective at reducing the rate
and size of metastasis, without changing the volume of the primary tumor [258,259]. In addition
to reducing metastasis, buffering with sodium bicarbonate increased breast tumors sensitivity to
doxorubicin and mitoxantrone, chemotherapies known to be ineffective in acidic tumor
environments [25,258,260]. A similar reduction in metastasis was achieved using orally
available imidazole(IEPA) or lysine buffers in murine experimental metastasis models [261,262].
Buffer therapy will be more thoroughly detailed in Chapter 3 of this dissertation.
Manipulating the Microenvironment for Therapeutic Benefit
Combination therapy has been a long-standing strategy for the treatment of cancer
patients. Drug resistance to single agent regimens is a major obstacle in the clinic and
combination therapy aims to target more of a heterogeneous tumor, reducing the ability of a
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tumor to develop resistance. The commonality of phenotypic characteristics of the tumor
microenvironment between patients encourages the targeting of the microenvironment in
combination with other cytotoxic chemotherapies. In the earlier sections, I detailed a number of
approaches to target the tumor metabolic phenotype as well as describing strategies to
manipulate hypoxia (exacerbation of hypoxia metabolically or by reducing oxygen delivery) for
therapeutic benefit. In this section, we will describe additional combination therapies that
manipulate the metabolic or physiologic phenotype of cancers.
2DG, the glucose analog hexokinase inhibitor, has been unsuccessful as a single agent
chemotherapy in the clinic, but has recently been of interest as a sensitizer of cancer cells to
other chemotherapies or radiation therapy [263-266]. Targeting metabolic pathways or DNA
integrity through ionizing radiation (IR) or treatment with drugs like metformin in combination
with 2DG treatment can lead to significant antitumor effects [267,268]. Clinical studies have
verified that combination therapy of 2DG with IR is safe for patients, and reduced toxicity
associated with IR in some patients [269,270]. Preclinical studies using 2DG as a sensitizer are
promising; however, clinical studies investigating the efficacy need to be completed before 2DG
sensitizing treatment becomes routine.
VEGF inhibitors, and antiangiogenic inhibitors in general, have similarly unintended
effects on the tumor microenvironment, resulting in normalization of the tumor vasculature.
Vascular normalization, first described by Rakesh K. Jain, is a maturation of existing immature
vessels within a tumor when neoangiogenesis is inhibited [166,271,272]. Vascular maturation
results in better oxygen delivery and tumor perfusion, relieving interstitial tumor pressure which
is hypothesized to provide better drug delivery to patients and reduce resistance to chemotherapy
[272]. Treatment of tumor bearing mice with VEGF inhibitor DC101 resulted in tumor vascular
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remodeling, where vasculature became nonleaky and more organized [273]. Further studies have
been conducted to study the timing of vascular normalization with optimal sensitivity to
radiation treatment [274,275]. Vascular normalization has been observed in patients with
nonmetastatic rectal adenocarcinoma receiving bevacizumab [276-278].
Although tumor reduction was not observed, microvessel density and vascular
permeability decreased and histological analysis confirmed the presence of mature vasculature
within tumors. Preclinical and clinical studies have provided support for the vascular
normalization hypothesis; however, more studies need to be completed to fully optimize the
normalization window to improve efficacy of this treatment.
Conclusion
Initially a barrier during carcinogenesis, the tumor microenvironment during the later
stages of carcinogenesis provides an advantage for a tumor to outcompete normal tissue,
becoming more aggressive and metastatic. Additionally, common characteristics of a tumor
microenvironment provide a haven of protection for a tumor against chemotherapies. The
immature and chaotic vasculature that exacerbates hypoxia within a tumor also provides minimal
perfusion through a tumor for effective drug therapy, and extracellular acidosis due to
preferential metabolism through aerobic glycolysis creates an environment that effectively traps
weakly basic drugs from moving intracellularly. Extensive research has been focused on
targeting the tumor microenvironment, providing clinicians with chemotherapies that target the
glycolytic pathway, acidosis, hypoxia, and hypoxia response pathways (Table 2.1).
Manipulation of the tumor microenvironment has been an effective strategy for the treatment of a
wide range of patients and will continue to be an important area of drug discovery in the future.
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CHAPTER 3
MECHANISMS OF BUFFER THERAPY RESISTANCE

Note to Reader
Portions of this chapter have been previously published in Neoplasia 2014, 16:354-364
[279]; and 2013, 15:1125-1137 [280]; Advances in Pharmacology 2012, 65:63-107 [34];
Journal of Cancer Science & Therapy 2011, Suppl 1:S1-004; and Journal of Nutrition & Food
Sciences 2012, S2 [281] and are utilized with permission of the publisher.

Introduction
Altered Tumor Metabolism
Otto Warburg first described an increased rate of aerobic glycolysis followed by lactic
acid fermentation in cancer cells in 1924, later termed the Warburg Effect [23]. Almost a
century of research has confirmed Warburg’s initial observation, solidifying increased glycolytic
flux as a common cancer phenotype [29]. Elevated expression of glycolytic genes are observed
in ~70% of human cancers [282]. Warburg hypothesized the metabolic shift away from oxidative
phosphorylation was due to mitochondrial dysfunction, yet this has not been substantiated [283].
While interest in cancer metabolism peaked in the middle part of the twentieth century, interest
waned with the advent of molecular biological techniques in the 1970s. In 1976, Sidney
Weinhouse famously declared that “Since our perspectives have broadened over the years, the
burning issues of glycolysis and respiration in cancer now flicker only dimly” [284]. The
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development of 18F-fluorodeoxyglucose (18FDG)-PET imaging to visualize increased glucose
uptake in tumors and metastasis has rekindled interest in cancer metabolism, and is commonly
used clinically for diagnosis and disease monitoring [285].
At first glance, the switch of glucose metabolism from oxidative phosphorylation to
aerobic glycolysis seems paradoxical. Aerobic glycolysis is a significantly less efficient method
to generate ATP from glucose than oxidative phosphorylation. For tumor cells that likely have
reduced access to nutrients and are proliferating quickly, effective use of available nutrients is
paramount. Significant effort has focused on understanding the altered metabolic phenotype and
its benefit to proliferating tumor cells.
Aside from ATP production, many biochemical intermediates are produced from glucose
metabolism that contribute to biomass production. Anabolic pathways are essential pathways for
proliferating cells, and are likely one of the key reasons glucose is metabolized so differently
than normal cells. Following phosphorylation by hexokinase, glucose-6-phosphate (G-6-P) can
be shuttled through the pentose phosphate shunt for nucleotide synthesis, producing NADPH
(nicotinamide adenine dinucleotide phosphate, reduced) during the process. Movement of G-6-P
through the pentose phosphate shunt is facilitated in part by tumoral expression of pyruvate
kinase M2 (PKM2), the final enzyme in glycolysis that catalyzes the transfer of phosphate from
phosphoenolpyruvate (PEP) to ATP and producing pyruvate [192]. Importantly, PKM2 is a less
efficient enzyme than its isoform PKM1 that is expressed in normal tissue, and is negatively
regulated by oncogenic tyrosine kinase signaling pathways [192,286]. A reduction in efficiency
during the final steps of glycolysis creates a bottleneck in the glycolytic pathway, and redirects
G-6-P into the pentose phosphate pathway, allowing for nucleotide synthesis, an essential
requirement for proliferating cells.
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An alternate hypothesis has been proposed by Epstein et al to explain the Warburg Effect
from an energetic perspective [287]. They propose that increased aerobic glycolysis in cancer
cells serves to meet rapidly changing energetic demands from membrane pumps. Oxidative
phosphorylation, while extremely efficient, is very slow to increase throughput to meet acute
increases in energetic demand. They propose that cancer cells use oxidative phosphorylation to
maintain the baseline energy demands, while using glycolysis to feed ATP to membrane pumps
on demand during proliferation and migration. This hypothesis is supported by the localization
of key glycolytic enzymes near the membrane of cells, and a rapid increase in glycolytic flux
upon stimulation of membrane transporters.
Any pyruvate that is produced during glycolysis has several potential metabolic fates.
Through aerobic glycolysis, pyruvate is converted to lactate by lactate dehydrogenase, which
will be discussed more thoroughly below. Alternatively, pyruvate can pass through the
mitochondrial membrane, where it is converted into acetyl-CoA by pyruvate dehydrogenase.
Entry into the TCA cycle requires further conversion to citrate, which can also be shuttled back
into the cytoplasm under high ATP/ADP and NADH/NAD+ conditions found in proliferating
cells [192,288], and converted into acetyl-CoA. Once in the cytoplasm, acetyl-CoA is used for
amino acid and lipid synthesis, essential anabolic pathways for proliferating tumor cells. In
addition to biomass production, the alternative metabolic pathways described above, generate
NADPH. NADPH is required for macromolecular synthesis and is an important regulator of the
cellular redox state which is often disrupted in tumors [289].
Tumor Acidosis and the Metastatic Cascade
Lactate is the canonical product of aerobic glycolysis, produced from pyruvate by lactate
dehydrogenase. Lactate production is the most common fate of glucose, and accounts for as
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much as 90% of glucose taken in by glioblastoma cells [290]. Lactate has traditionally been
considered a waste product of glycolysis and is shuttled extracellularly with H+, to maintain
intracellular pH (pHi). Tumors frequently upregulate membrane proton pumps to export excess
intracellular acid, including monocarboxylate and proton transporters, sodium-hydrogen
exchangers (NHE), anion exchangers (AEs), vacuolar ATPases (V-ATPases), and membranebound carbonic anhydrases (CAs) [218,253,291]. One such transporter, carbonic anhydrase-9
(CA-IX) is a negative prognostic indicator in many cancers [292,293]. Proton and lactic acid
export, combined with poor vascular perfusion, cause the tumor to become highly acidic (pH 6.5
- 6.9) relative to the physiological pH of normal tissues (pH 7.2-7.5) [15,16]. Acidic
microenvironments have been shown to increase cellular motility and invasiveness of a tumor,
leading to increased metastasis [26,216,217].
Progression to metastatic disease remains the highest mortality risk for cancer patients,
despite significant efforts to therapeutically target metastatic lesions [29,294]. Metastatic disease
involves the movement of cancer cells from the primary tumor into secondary growths in distant
organs. The process, known as the metastatic cascade, involves a series of steps involving: 1)
acquisition of an invasive phenotype and invasion into the local stroma around the primary tumor
site; 2) intravasation into vasculature; 3) survival of circulating tumor cells (CTCs) in the
vasculature; 4) extravasation into the secondary organ; and 5) colonization and growth in the
secondary organ site to form a successful metastasis. While metastatic disease is a fairly
common clinical phenomenon, metastasis is a highly inefficient process. The vast majority of
cancer cells that begin movement away from the primary tumor will die throughout the process,
and < 0.01% will succeed to form full fledge metastasis in secondary organs [294]. Interestingly,
the latency period for the metastatic cascade varies widely across cancer types. For instance,
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breast cancer metastasis usually occurs over years, even decades; while lung or melanoma
patients suffer metastatic dissemination much faster and is sometimes present at diagnosis. In
fact, the recurrence-free survival rate for patients with stage I breast cancer is 94% [295], while
stage I lung adenocarcinoma patients are around 75% [296] and melanoma patients usually
reoccur within 2 years [297,298]. Another phenomenon commonly observed in metastatic
disease is the frequency with which cancers commonly metastasize to the same secondary
organs. Metastatic disease is often confined to specific secondary organs, which is dependent on
the primary cancer type. For example, breast cancers typically metastasize to the brain, bone,
liver and lungs; while colorectal and pancreatic cancers metastasize to the liver and lungs (Table
3.1). The complexity of the metastatic cascade, including latency and secondary organ site
variability, has encouraged significant efforts to find similarities in the mechanisms of metastasis
across tumor types with the ultimate goal of treating or preventing metastatic disease.

Table 3.1 Common Sites of Metastatic Disease
Cancer Type
Breast Cancer
Prostate Cancer
Lung Cancer
Colorectal Cancer
Melanoma

Site of Metastatic Disease
Bone, lungs, liver & brain
Bone
Brain, bone, & liver
Liver & lungs
Lungs, brain, skin & liver

[299-303]
[304]
[305]
[306]
[307]

Proteases and Metastatic Disease
A class of enzymes, proteases, has received significant attention due to their widespread
role in the metastatic cascade. Acidity and proteases are tightly linked when described in the
“acid-mediated invasion” hypothesis which proposes that acidification of the tumor
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microenvironment can be associated with cathepsin release to trigger matrix remodeling [291].
This dissertation will focus specifically on two classes of proteases, matrix metalloproteinases
(MMPs) and cysteine cathepsins. MMPs are zinc-dependent endopeptidases. Their
overexpression has been observed in a number of tumors and is a predictor of progression to
metastatic disease [308-310]. MMPs are transcribed as pro-enzymes that must be activated,
either by proteolytic cleavage or chemical modifications, which can occur intracellularly or
extracellularly after secretion [308,311]. MMPs are regulated through multiple levels; through
gene expression, compartmentalization intracellularly and extracellularly, activation of proenzyme to active enzyme, and by the presence of tissue inhibitors of metalloproteinases (TIMPs)
[285]. MMPs breakdown components of the extracellular matrix (ECM), and have been shown
to participate in every step of the metastatic cascade [308]. Due to the extensive involvement of
MMPs in the metastatic cascade, and the ability to target MMP enzymes with small molecules
[312], clinical trials began in earnest in the 1990s. Unfortunately, clinical use of MMP inhibitors
(MMPi) were largely considered a failure for a variety of reasons [313]. First, timing of MMPi
administration in the process of cancer progression is essential for efficacy, and clinical trials
were not designed with this in mind [260,314]. Pre-clinical models showing efficacy of MMPi
were treated during the early stages of cancer development and progression, while clinical trials
were conducted in end-stage patients with widespread disease [315-317]. Second, broad
inhibitor activity towards multiple MMPs resulted in dose-limiting toxicities in trials, which may
be alleviated with more specific inhibitors [312,314].
Another type of protease, cysteine cathepsins, are lysosomal in origin but can be excreted
into the tumor microenvironment, where they degrade the ECM [318-320]. Cysteine cathepsins,
like MMPs, have been implicated in cancer progression and metastasis through their interaction
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in complex networks and protein signaling pathways [321,322]. Regulation of cysteine
cathepsins occurs at the gene expression level [323], localization intracellularly and
extracellularly, activation of pro-enzymes to activate the enzymatic activity, and through
endogenous inhibitors [322]. Of particular interest to the work in this thesis, Cathepsin B
expression and activity has been shown to be regulated by pH. The pH of the tumor
microenvironment regulates the secretion of Cathepsin B into the microenvironment, which has
been linked to tumor progression [324,325].
Recently, Rothberg et al. characterized the impact of the acidic tumor microenvironment
on the release of active Cathepsin B from MDA-MB-231 cells into the pericellular tumor
microenvironment [280]. Live-cell proteolytic imaging techniques [326] were used to confirm
increased degradation of DQ-collagen IV upon exposure to acidic culture. A fluorescent
activity-based probe, GB-123 [327], that binds active Cathepsin B confirmed pericellular
localization of active Cathepsin B under acidic conditions. To determine if Cathepsin B activity
is regulated by pHe in vivo, GB-123 was used to quantify Cathepsin B activity in tumors. Mice
bearing orthotopic MDA-MB-231 tumors were provided tap water or 200 mM bicarbonate (to
raise the pHe of the tumors). Tap treated mice had significantly more GB-123 within their
tumors, confirming that acidic tumor conditions increase Cathepsin B activity in vivo (Figure
3.1), and that treatment with buffer therapy can reduce Cathepsin B activity by increasing pHe.
Cellular Migration in Metastasis
Cell migration through tissue can occur through different mechanisms, either as single cells or in
a collective fashion [328,329]. Cell migration patterns have been further classified based on
cellular morphology of rounded and elongated cell types in 3D culture systems as well as in-vivo
tumor models [330]. Additionally, tumor acidity and expression of proton pumps have
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Figure 3.1 In vivo buffering of tumor pHe reduced tumor binding of GB123. (A) Enlarged
representative florescent images of MDA-MB-231 orthotopic tumors showing retention of
GB123 18 hours post-injection. (B) Average normalized counts of GB123 retained in MDAMB-231 orthotopic tumors ± SEM; a one-tailed unpaired t test was used to determine
significance, p = 0.03

been associated with increased cellular migration and invasion in breast and melanoma cell lines
[331-333].
Manipulating Tumor Acidosis with Systemic Buffer Therapy
As acidosis is a common phenotype in solid tumors, we have developed a strategy to
neutralize acidity using orally ingested buffers [257]. We have shown previously that treatment
of mice with orally available buffers is efficacious in reducing spontaneous and experimental
metastasis by increasing extracellular pH (pHe) due to higher buffering capacity of blood [259].
This is a targeted effect, as it only brings into balance the pH of tissues that were previously out
of the physiological range [257]. Increased tumor pHe following treatment with oral buffers has
been confirmed through MRI and microelectrodes [259,261]. Sodium bicarbonate (pKa=6.4), 243

imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA) (pKa=6.9), and free-base lysine
(pKa=10) have all been shown to be effective in reducing metastases in-vivo [259,261,334].
Initial studies focused on the reduction on metastasis formation following treatment with
buffer therapy, as there was no observable reduction in tumor volume reduction [259]. Further
studies using a genetically engineered prostate cancer model [Transgenic Adenocarcinoma of the
Mouse Prostate (TRAMP)], however, show that carcinogenesis can be inhibited by buffer
therapy [262]. The timing of buffer therapy initiation proved to be imperative for optimal
efficacy. When TRAMP pups were administered buffer therapy early, at 4 weeks of age,
development of prostate tumors was potently inhibited. If buffer therapy was delayed until the
TRAMP mice were 10 weeks of age, the therapy was ineffective in preventing tumor formation.
Importantly, mice that were treated at 10 weeks of age still benefited from treatment with buffer
therapy, as metastatic formation was significantly inhibited. Future studies to optimize buffer
therapy regimens are necessary to fully understand the potential for clinical efficacy of buffer
therapy.
Treatment with buffer therapy is non-toxic, as mice maintain their weight, blood pH,
renal function and immune cell distribution throughout the course of treatment [259,261,334].
While non-toxic, treatment with sodium bicarbonate may be of concern for patients suffering
from hypertension, due to the excess sodium counter-ion that is simultaneously dosed with
bicarbonate. Treatment with alternate buffers, such as lysine, tris, or IEPA, would overcome this
limitation, though likely at a higher cost of treatment. Of the currently available buffers, lysine
is the most efficacious as it has the highest pKa of the three [257].
To confirm that buffer therapy reduces metastasis formation through buffering, the
buffering capacity of free-base lysine was significantly reduced by lowering the pH from pH
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10.0 to pH 8.4 (below the second pKa) prior to treatment of mice. Mice were then injected with
luciferase expressing PC3M cells via tail vein injection in an experimental metastasis model.
Metastatic formation was measured weekly by bioluminescent imaging, which showed that
reducing the buffering capacity of lysine rendered the therapy significantly less effective in
preventing metastatic formation than lysine pH 10 (Figure 3.2) [281]. This experiment confirms
that buffering capacity is required for efficacy of buffer therapy in reducing metastatic formation.
Notably, the efficacy of buffer therapy is not universally observed. Metastases in two
cell lines; MDA-MB-231, human breast adenocarcinoma; and PC3M, prostate adenocarcinoma;
are both inhibited by buffer therapy, while B16-F10 cells, murine melanoma, and LL/2 cells,
murine lung carcinoma, were resistant to the same treatment [259,261,334]. The success of
buffer therapy suggests that, at least in sensitive cells, there is a metastatic mechanism that has an
acidic pH optimum. This study investigates the mechanisms of buffer therapy resistance. The
observation that buffering is not universally efficacious led us to hypothesize that resistant and
sensitive lines utilize different metastatic mechanisms, one that is pH-independent and one that is
pH-dependent. Metabolic profiling confirms that buffer-sensitive lines have a much more robust
glycolytic phenotype, compared to resistant lines, and that this is coupled to increased tumor
acidification. In contrast, resistant lines constitutively expressed proteases in a pH-independent
fashion, compared to sensitive lines whose protease activities were low and pH-dependent.
Acidic pHe results in morphological changes in sensitive cells, while resistant cells were
unaffected. We propose that sensitive cells activate proteases and alter their morphology by
acidifying their microenvironment, which can be inhibited by buffer therapy and that resistant
cells have constitutively active protease release.
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Figure 3.2 Lysine free base reduces metastases through pH buffering. SCID mice were divided
into two cohorts: tap water and lysine, which received supplementation of lysine free base in
drinking water at pH 8.4. Both groups were injected with bioluminescent PC3M cells one week
following initiation of treatment. (A) Representative bioluminescent images of mice receiving
tap water or lysine pH 8.4 throughout the course of the experiment. (B) Lysine was titrated to
pH 8.4 using HCl (1N), a pH at which the pH buffering capacity is significantly reduced (β10.0 =
8.5 mEq vs β8.4 = 1.5 mEq). Lethal burden thresholds for survival curves were set at 3-fold
background signal (Rose criterion), which was set by the measuring the bioluminescent signal
one week post injection. (C) Survival curve of mice treated with lysine pH 10.0 showed a
significant increase in overall survival compared to tap water (p = 0.004). (D) Survival curve of
mice treated with “de-buffered” lysine pH 8.4 showed a reducing in survival benefit compared to
the control group (p = 0.04). Log-rank (Mantle-Cox) tests were used to determine significance of
survival data.

Results
Efficacy of Lysine Buffer Therapy is not Universal
We have previously shown that experimental metastasis of PC3M cells was inhibited by
200 mM lysine (pH = 10.1) (performed by Arig Ibrahim Hashim) (Figure 3.3) [281,334].
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Figure 3.3 Sensitivity of PC3MS to treatment with lysine buffer therapy. (A) Representative
bioluminescent images of PC3MS metastasis in SCID mice. (B) Ex vivo bioluminescent imaging
of PC3MS metastasis. (C) Graphic representation of bioluminescent imaging of PC3MS
metastasis. Data is reported as log photons/sec ± SEM. S, sensitive
Importantly, we have shown previously that neutralized lysine (pH = 8.4) was much less
effective in preventing metastases than lysine (pH = 10.1), showing the effect was due to
buffering capacity (Figure 3.2) [281]. In the current study, we sought to identify additional
lysine-sensitive and -resistant cell lines using experimental metastasis models. Mice were
pretreated with 200mM lysine or tap water for one week prior to intravenous injection of Fireflyluciferase expressing cells in an experimental metastasis model. Metastasis formation was
monitored weekly or bi-weekly with bioluminescent imaging, and presence of metastasis was
confirmed with ex vivo imaging post-mortem and histological analysis. Consistent with previous
work, B16-F10 metastasis were unaffected by lysine treatment (Figure 3.4) [259]. LL/2 cells
were similarly unresponsive to lysine treatment, showing no difference in metastasis formation
or survival benefit with treatment (Figure 3.5). MDA-MB-231 cells experienced significantly
lower metastatic burden following therapy (p < 0.05), which translated into a significant survival
benefit (p < 0.05) (Figure 3.6). HCT116 cells had not previously been tested using an
experimental metastasis model, but had shown a reduction in local invasion in a window47

Figure 3.4 Resistance of B16-F10R to treatment with lysine buffer therapy. Effect of lysine was
determined by pre-treating SCID-beige mice for a week before tail vein injection of B16-F10R
cells stably expressing Firefly-luciferase in an experimental metastasis model. Treatment of 200
mM lysine was administered continuously throughout the experiment. Bioluminescent imaging
of B16-F10R metastasis (Tap n = 10, Lysine n = 10) shows buffer therapy is ineffective (left).
Representative bioluminescent images of one mouse per cohort are shown throughout the course
of the experiment (right). Metastasis formation was measured by bioluminescent imaging,
reported as log photons/sec ± SEM. R, resistant
chamber model when treated with 200mM bicarbonate [291]. In contrast to those results,
treatment of mice with lysine had no effect on HCT116 metastatic formation or survival (Figure
3.7). From this point on, cells will be identified as resistant or sensitive to lysine buffer therapy
with subscripts (ResistantR; SensitiveS).
In vitro characterization of Lysine Buffer Therapy Resistant and Sensitive Cell Lines
We subsequently performed in vitro studies to identify potential mechanisms of resistance.
Profiling cell lines in vitro confirmed that cultured cells resemble cells grown in vivo, giving us
confidence that mechanisms identified in vitro translate in vivo. For example, growth rates of
resistant cells (B16-F10R, LL/2R and HCT116R) were significantly higher compared to sensitive
cells (PC3MS and MDA-MB-231S) (p < 0.001) (Figure 3.8A). The in vitro growth curves
closely followed in vivo growth rates, with B16-F10R and LL/2R expanding significantly faster
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Figure 3.5 Resistance of LL/2R to treatment with lysine buffer therapy. Effect of lysine was
determined by pre-treating SCID-beige mice for a week before tail vein injection of LL/2R cells
stably expressing Firefly-luciferase in an experimental metastasis model. Treatment of 200 mM
lysine was administered continuously throughout the experiment. (A) Bioluminescent imaging
of LL/2R metastasis (Tap n = 10, Lysine n = 10) shows buffer therapy is ineffective. (B)
Representative bioluminescent images of one mouse per cohort are shown throughout the course
of the experiment. (C) Kaplan Meier curve showing survival of experimental metastasis model
of LL/2R. Metastasis formation was measured by bioluminescent imaging, reported as log
photons/sec ± SEM. R, resistant

Figure 3.6 Sensitivity of MDA-MB-231S to treatment with lysine buffer therapy. Effect of
lysine was determined by pre-treating SCID-beige mice for a week before tail vein injection of
MDA-MB-231S cells stably expressing Firefly-luciferase in an experimental metastasis model.
Treatment of 200 mM lysine was administered continuously throughout the experiment. (A)
Bioluminescent imaging of MDA-MB-231S metastasis (Tap n = 5, Lysine n = 8) shows buffer
therapy is effective. (B) Representative bioluminescent images of one mouse per cohort are
shown throughout the course of the experiment. (C) Kaplan Meier curve showing increased
survival of MDA-MB-231S upon treatment with lysine. Metastasis formation was measured by
bioluminescent imaging, reported as log photons/sec ± SEM. * p = < 0.05; S, sensitive
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Figure 3.7 Resistance of HCT116R to treatment with lysine buffer therapy. Effect of lysine was
determined by pre-treating SCID-beige mice for a week before tail vein injection of HCT116R
cells stably expressing Firefly-luciferase in an experimental metastasis model. Treatment of 200
mM lysine was administered continuously throughout the experiment. (A) Bioluminescent
imaging of HCT116R metastasis (Tap n = 8, Lysine n = 10) shows buffer therapy is ineffective.
(B) Representative bioluminescent images of one mouse per cohort are shown throughout the
course of the experiment. (C) Kaplan Meier curve showing survival of experimental metastasis
model of HCT116R. Metastasis formation was measured by bioluminescent imaging, reported as
log photons/sec ± SEM. R, resistant
than PC3MS and MDA-MB-231S (p < 0.0001) (compare Figures 3.3-3.6 with Figure 3.8A),
and HCT116R growing at an intermediate rate (Figures 3.7 and 3.8A). While culturing cells, it
was apparent that there were differences in the size of the resistant and sensitive cells, which
may contribute to increased metastasis through increased extravasation from the vasculature.
Cell size was measured while free in suspension to estimate their size in circulation, showing
resistant cells were significantly smaller than sensitive cells (p < 0.05) (Figure 3.8B), which may
allow for more rapid extravasation during metastasis.
Effect of pHe on Invasion Rates of Resistant and Sensitive Cells
Buffer therapy selectively increases the pHe of tumors, hence, we sought to determine the
effect of pH on invasion in vitro [259,261]. Cells were fluorescently labeled with 10 µg/ml of
DilC12(3) prior to seeding in the apical chamber of a Boyden chamber system in serum-free
media. pH 6.8 or pH 7.4 media containing serum (as a chemo-attractant) was placed in the basal
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Figure 3.8 In vitro characterization of lysine buffer therapy resistant and sensitive cell lines. (A)
Average cell growth curves measured over 72 hours indicates significant growth rate differences
between resistant and sensitive cells and correlate with in vivo tumor growth rates. Data shown
as mean cell number ± SD. (B) Cell diameter measurements of single cells in suspension show
resistant cells are significantly smaller than sensitive cells. Data shown as mean cell diameter
(µm) ± SD. * p < 0.05; *** p < 0.001; **** p < 0.0001; R, resistant; S, sensitive.
chambers. A FluoroBlok™ membrane below a layer of matrigel enabled me to kinetically
measure cell invasion over 48 hours using a fluorescent reader. Uptake of fluorescent dye had
no adverse effect on cell proliferation (data not shown). Invasion rates were measured for each
cell line and analyzed to determine the differential rate of invasion between each pH condition,
in order to self-normalize for differences in uptake of the fluorescent dye across cell lines.
Resistant cells, B16-F10R, LL/2R, and HCT116R showed no significant change in their rates of
invasion between pH 6.8 and pH 7.4 (Figure 3.9). MDA-MB-231S cells, however, had a
significantly increased rate of invasion at pH 6.8, relative to pH 7.4, when compared to B16F10R (p < 0.05), LL/2R (p < 0.05), and HCT116R (p < 0.005) (Figure 3.9). While not statistically
significant, PC3MS cells followed the same trend as MDA-MB-231S cells of having an increased
rate of invasion at pH 6.8 relative to pH 7.4 (Figure 3.9). As growth rates are suppressed under
hese acute acidic conditions for each cell line (data not shown), we conclude that the increased
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Figure 3.9 Effect of pHe on invasion rates of resistant and sensitive cells. In vitro invasion assay
using a Boyden chamber coated with Matrigel. Fluorescently labeled cells were measured every
6 hours for 48 hours for invasion through Matrigel layer. Data shown is the result of two
biologic experiments (n = 6/sample) normalized to wells lacking serum attractant (n = 2/sample).
Data is presented as the mean difference in the rate of invasion of cells cultured in pH 6.8 and
cells cultured in pH 7.4 ± SD. The rate of invasion of sensitive cells increases in pH 6.8
compared to resistant lines. *p < 0.05; **p < 0.005; R, resistant; S, sensitive.
invasion rate in sensitive cell lines is a real phenomenon, and not the result of growth rate
differences. Together, these data suggest that resistant and sensitive cells utilize different
invasive mechanisms, pH-independent and pH-dependent mechanisms, respectively.
Analysis of the Metabolic Phenotypes of Resistant and Sensitive Cells
The Warburg Effect is a common phenomenon in solid tumors that contributes to
acidification of the tumor microenvironment. Originally, we hypothesized resistant lines would
produce acid at a higher rate, implying that increasing the buffer load could overcome buffer
resistance. To test this, we examined the effect of 400 mM bicarbonate on experimental B16F10R metastasis formation and observed no effect (data not shown); suggesting resistant cells
were not merely producing acid at a higher rate. This was verified by metabolic profiling of
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resistant and sensitive cells using a Seahorse XF® analyzer which measures real-time H+
production and oxygen consumption rate over a monolayer of cells in a transient microchamber.
Metabolic profiling assays were performed in parallel and normalized assay data to either cell
number or protein concentration, to confirm that normalized results were not an artifact of cell
size differences (data not shown). To determine glycolytic activity, a “glycolytic stress test”
was performed, which includes measuring extracellular acidification rates (ECAR) following
sequential addition of glucose to measure basal glycolysis, a mitochondrial poison (oligomycin)
to estimate total glycolytic capacity, and 2-deoxyglucose to measure non-glycolytic ECAR.
Interestingly, sensitive cells had significantly higher basal glycolytic rates, compared to resistant
cells (p < 0.0001) (Figure 3.10A). Glycolytic reserve is calculated by measuring the difference
in the maximal glycolytic capacity, after treatment with oligomycin, and basal glycolysis.
Possibly as a consequence of their high basal rates, the sensitive cells showed significantly lower
amounts of glycolytic reserve, compared to resistant cells (p < 0.0001), suggesting that they are
near maximum glycolytic capacity in their basal metabolic state (Figure 3.10B).
The rate of decrease in O2 can be converted to an oxygen consumption rate, OCR. The
“mitochondrial stress test” initially determines basal respiration. We observed that resistant cells
had significantly higher basal OCR compared to sensitive cells (p < 0.05) (Figure 3.11). We
suspect that the higher basal OCR in resistant cells is most likely related to the energy demands
of a higher proliferation rate (Figure 3.8). Treatment with an inhibitor of the F0 subunit of
mitochondrial ATP synthase, oligomycin, provided OCR attributed directly to ATP production.
These data showed that buffer therapy resistant cells had significantly higher OCR that attributed
to ATP production (p < 0.0001) (Figure 3.11). These mitochondrial stress test data suggest that
resistant cells rely on mitochondrial oxidative metabolism (OXPHOS) for their energy needs.
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Figure 3.10 Glycolytic profile analysis of buffer therapy resistant and sensitive cells. In vitro
extracellular acidification rate (ECAR) of resistant and sensitive cells, measured using Seahorse
XF-96 Instrument. Metabolic data are presented as mean ± SD. (A) ECAR measurements in
response to 5.55 mM glucose stimulation indicate basal glycolytic activity of cells. Sensitive
cells are significantly more glycolytic than resistant cells. (B) The increase in ECAR of cells in
response to treatment with 1 µM oligomycin minus basal glycolytic activity indicates the
glycolytic reserve of cells. Sensitive cells have significantly reduced glycolytic reserve
compared to resistant cells. ****p < 0.0001; R, resistant; S, sensitive.
Metabolic analysis of OXPHOS and glycolytic pathways in resistant and sensitive cells showed
distinct metabolic profiles. This can be directly shown by expressing data as basal OCR/ECAR
ratios, which are self-normalized and showed that sensitive cells were significantly (p < 0.005)
more glycolytic than resistant cells (Figure 3.12A). These differences in metabolic profiles were
related to the ability of buffer therapy to inhibit metastasis (Figures 3.3-3.7), and correlate with
distinct phenotypic differences in their in vivo and in vitro proliferation rates (Figure 3.8A), and
size (Figure 3.9A). pHe measurements of PC3MS and B16-F10R tumors (performed by Heather
H. Cornnell) support the metabolic evidence presented, with PC3MS tumors being more acidic
than B16-F10R tumors (Figure 3.12B). Previous studies, using MRS imaging with the pH
indicator 3-aminopropylphosphonate (3-APP) and fluorescent ratio imaging with SNARF-1,
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Figure 3.11 Oxidative profile analysis of buffer therapy resistant and sensitive cells. In vitro
oxygen consumption rate (OCR) of resistant and sensitive cells, measured using Seahorse XF-96
Instrument. Metabolic data are presented as mean ± SD. (A) Basal OCR measurements show
significantly higher oxidative phosphorylation flux in resistant cells compared to sensitive cells.
(B) OCR contributing to production of ATP during oxidative phosphorylation is measured by the
difference of basal OCR and the OCR of cells after treatment with 1 µM oligomycin, a
mitochondrial ATP synthase inhibitor. The amount of OCR contributing to the production of
ATP by oxidative phosphorylation is significantly higher in resistant cells compared to sensitive
cells. *p < 0.05; ****p < 0.0001; R, resistant; S, sensitive.
have shown that MDA-MB-231 tumors are similarly acidic and can be manipulated with buffer
therapy to increase the tumor pH [259]. We have previously observed sensitivity of HCT116GFP cells to bicarbonate in window-chamber studies [291], but observed clear resistance of
HCT-116R-Luc cells in our current studies (Figure 3.7). Interestingly, HCT116-GFP cells had a
different metabolic profile than the HCT116R-Luc cells used in the in vivo experimental
metastasis model herein, suggesting the presence of two phenotypically distinct populations of
these cells, supported by differences in their OCR/ECAR ratios (p < 0.0001) (Figure 3.13).
Importantly, DNA fingerprinting confirmed that both lines used were HCT116 colorectal cells
(data not shown). Notably, the glycolytic HCT-116-GFP cells were inhibited by buffer therapy
[291]; whereas the oxidative HCT-116-luc cells were not (Figure 3.7).
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Figure 3.12 Sensitive cells are more glycolytic than resistant cells, leading to tumor acidosis.
(A) The OCR/ECAR ratio of cells during basal metabolism indicates that sensitive cells are
significantly more glycolytic than resistant cells. (B) Intratumoral pH measurements of
subcutaneous tumors using pH electrodes shows that increased glycolytic activity of sensitive
cells, PC3MS, contributes to a more acidic tumor microenvironment than resistant tumors, B16F10R. pH data are presented as mean of independent measurements (B16-F10R n = 10; PC3MS n
= 5) ± SEM. ****p < 0.0001; R, resistant; S, sensitive
In vivo Proteolytic Activity in Resistant and Sensitive Tumors
Invasion kinetics and metabolic profiling suggest that resistant cells invade via a
mechanism that is pH-independent. Proteases have been identified as key enzymes involved in
the metastatic cascade. Prior data have shown that low pH significantly stimulated the release of
active cathepsin-B from buffer-sensitive MDA-MB-231 cells in 2-D and 3-D culture [259,335].
Hence, we hypothesize that resistant cells may release active proteases in a constitutive, pHindependent fashion. To investigate this, mice bearing tumors were imaged using fluorescent
indicators that are activated by protease activity. ProSense 750EX and MMPsense 680 fluoresce
upon cleavage by Cathepsins B, L, S and Plasmin (ProSense 750EX) or MMPs -2, -3, -9 and -13
(MMPsense 680). Using a tomographic near-IR fluorescence imaging system, FMT2500,
activated probes were imaged 24 hours post-probe injection followed by fluorescent signal
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Figure 3.13 Metabolic profile analysis of HCT116-Luc and HCT116-GFP cells. Glycolytic and
mitochondrial stress tests show different metabolic profiles of HCT116-Luc and HCT116-GFP
cells. (A) Extracellular acidification rates (ECAR) of cells after stimulation of glycolysis with
glucose (5.55 mM), oligomycin (1 µM) and glycolysis inhibitor 2DG (100 mM). (B) Oxygen
consumption rates (OCR) of cells before treatment with oligomycin (1 µM), FCCP (1 µM) and
Rotenone (1 µM) and Antimycin A (1 µM). (C) OCR/ECAR ratio of cells during basal
metabolism. (D) Representative brightfield microscopy images of HCT116-Luc and HCT116GFP cells in pH 7.4 culture conditions. Data shown as mean ± SD. Scale bars represent 100
µm. ****p < 0.0001

integration over the tumor region of interest (ROI). B16-F10R tumors were not used due to high
melanin levels that quench fluorescence. Thus, the in vivo protease activity was measured in the
most resistant (LL/2R) and the most sensitive (PC3MS) cell lines (Figure 3.3 and Figure 3.5).
Quantification of activated ProSense 750EX in LL/2R tumors showed significantly higher
cysteine cathepsin activity compared to PC3MS under control conditions (p < 0.0001) (Figure
3.14). Although treatment reduced ProSense 750EX activation in LL/2R tumors (p < 0.05),
activity still remained significantly higher than PC3MS cells under either pH condition (Figure
3.14) [318]. Conversely, MMPsense 680 was visibly activated in both LL/2R and PC3MS tumors
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in control mice (Figure 3.15). Buffer treatment increased MMP activity in LL/2R tumors (p <
0.05), and reduced MMP activity 2-fold in PC3MS tumors, but was not statistically significant
(Figure 3.15). Resistant LL/2R tumors had higher intrinsic cathepsin activity than did PC3MS
tumors and elevated MMP activity following buffer therapy. Therefore, we can conclude that
resistant lesions have more protease activity compared to sensitive lesions, which may be
contributing to buffer therapy resistance.
In vitro Protease Expression in Resistant and Sensitive Cells
To confirm in vivo protease activity results, cell cultures exposed to media at pH 7.4 or pH 6.8
were analyzed for MMP-2, -3, -9, and -13 (MMPs that activate MMPsense 680) mRNA
expression. We chose to focus on MMP expression due to the significant increase of MMP
activity observed upon treatment with lysine in LL/2R tumors (Figure 3.15). Both LL/2R and
PC3MS cells exhibited an increased expression of MMP-3 and -13 at pH 6.8 (Figure 3.16A). To
further compare differences, transcript expression was analyzed in LL/2R cells normalized to
PC3MS cultures. LL/2R cells have higher MMP expression compared to PC3MS cells for each of
the transcripts analyzed, with the exception of MMP-9 (Figure 3.16B). Importantly, there were
no differences in fold change of each transcript relative to PC3MS when exposed to acidic or
physiological conditions, showing that higher proteolytic expression of resistant cells was pHindependent. MMP transcript analysis confirms our hypothesis that buffer therapy resistant
lines are constitutively proteolytic in vitro (Figure 3.16) as well as in vivo (Figure 3.14 and
Figure 3.15).
The Effect of pHe on Resistant and Sensitive Cell Migration and Morphology
Recent research has focused on identifying different modes of migration and invasion during
metastasis [328]. To understand migratory differences between LL/2R and PC3MS,
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Figure 3.14 Resistant tumors have increased in vivo Cathepsin activity. Mice bearing LL/2R
(Tap n = 7, Lysine n = 8) and PC3MS (Tap n = 7, Lysine n =5) tumors were injected with an
activatable probe, ProSense 750EX, which reports Cathepsin activity. (A) Representative
images of fluorescent tomographic imaging showing cathepsin activity through ProSense 750EX
signal in LL/2R and PC3MS tumors in mice receiving either tap water or lysine buffer. (B)
Quantitation of ProSense 750EX activated signal in tumors, normalized to tumor size. Data are
presented as mean nanomolar concentration ± SD. *p < 0.05; ****p < 0.0001; R, resistant; S,
sensitive.

cell motility was monitored in a wound healing assay by imaging cells for 18 hours following
wound formation. Percent relative wound density was calculated by measuring the density of
cells that migrated into the original wound. LL/2R cells were significantly more migratory than
PC3MS cells cultured in physiologic pH (p < 0.0001) (Figure 3.17). Interestingly, exposure to
low pH had differential effects on cell migration for each of the cell lines. LL/2R migration
across the wound was significantly retarded under acidic conditions (p < 0.01), while PC3MS
cell migration was significantly accelerated under acidic conditions (p < 0.0001) (Figure 3.17).
Additionally, sensitive and resistant cells exhibited different modes of migration. PC3MS cells
moved across the wound as a mass following leading cells, suggestive of a collective cell
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Figure 3.15 Resistant tumors have increased in vivo MMP activity. Mice bearing LL/2R (Tap n
= 7, Lysine n = 8) and PC3MS (Tap n = 7, Lysine n =5) tumors were injected with an activatable
probe, MMPsense 680, which reports MMP activity. (A) Representative images of fluorescent
tomographic imaging showing MMP activity through MMPsense 680 signal in LL/2R and
PC3MS tumors in mice receiving either tap water or lysine buffer. (B) Quantitation of
MMPsense 680 activated signal in tumors, normalized to tumor size. Data are presented as mean
nanomolar concentration ± SD. *p < 0.05; **p < 0.01; R, resistant; S, sensitive.
migration phenotype, while LL/2R cells moved as single cells, which is characteristic of singlecell or multicellular streaming invasive phenotypes (data not shown). While studying the
movement of cells in a 2D culture environment is useful, 3D cultures more closely resemble
physiological obstacles encountered during metastasis. Using phalloidin staining, we studied the
morphology of LL/2R and PC3MS cells in a thick (500-1000 µm) layer of Matrigel® under
physiological or acidic conditions. In a 3D matrix LL/2R and PC3MS cells have distinctly
different cellular morphologies. PC3MS cells have an elongated phenotype with multiple
protrusions into the local matrix (Figure 3.18). In response to acidic conditions, PC3MS cells
maintained an elongated phenotype although completely void of the protrusions that were
observed under physiological conditions, which may allow for greater invasive potential. In
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Figure 3.16 Elevated MMP expression in resistant cells. Quantitation of MMP expression in
sensitive and resistant cells grown in physiological or acidic pH media for 24 hours. Transcripts
were normalized to β-actin expression before analysis. (A) Ratio of expression of MMP-2, -3, 9, and -13 in LL/2R and PC3MS cultured in acidic media relative to cells cultured in
physiological media. (B) Ratio of expression of MMP-2, -3, -9, and -13 in LL/2R cells relative to
expression in PC3MS cells cultured in acidic and physiological media. Data are the average of
three independent experiments and is reported as mean ± SD. *p < 0.05; R, resistant; S, sensitive
contrast, LL/2R cells had a rounded morphology that, consistent with the phenotypes we
characterized above, remain unchanged from physiologic to acidic pH (Figure 3.18).
Discussion
In our previous studies, we demonstrated that an acidic microenvironment is critical for
carcinogenesis and tumor invasion. Furthermore, we have found that systemic buffers reduce
intra- and peri-tumoral acidity, inhibit carcinogenesis in transgenic mice, and inhibit metastatic
growth in a wide range of cell lines in vivo [259,262,291]. However, as with most therapeutic
regimens, efficacy of buffer therapy was not universally observed. The current work focused on
identifying molecular and metabolic phenotypes of resistant cells, with an expectation that such
data could identify additional biomarkers to stratify tumors for their response to buffer therapy.
Using a panel of cells representing different cancers, we have characterized two responsive cell
lines, PC3MS and MDA-MB-231S, and three resistant cell lines, B16-F10R, and LL/2R, and
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Figure 3.17 Migratory patterns of LL/2R and PC3MS cells. 700- to 800-µm wounds were created
in confluent cell cultures exposed to physiologic or acidic media 24 hours before wound
formation, and during the duration of the experiment. Samples were imaged in 30-minute
intervals for 18 hours. (A) Representative microscopy images of LL/2R (upper panel) and
PC3MS (lower panel) show movement across a wound at 0 and 18 hours in pH 7.4 or pH 6.8
media. Scale bars represent 300 µm. (B) Percent relative wound density was determined by
measuring the density of cells within the original wound site at each of the time points imaged.
Data are shown as the mean ± SEM and are representative of three independent experiments.
**p < 0.01; ****p < 0.0001; R, resistant; S, sensitive.
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Figure 3.18 Morphologies in a 3D matrix in vitro. LL/2R and PC3MS cells were seeded onto a
thick (500-1000 µm) layer of polymerized Matrigel and invaded into the matrix over a period of
72 hours in pH 6.8 or pH 7.4 media. Single cells were imaged using confocal microscopy for
morphological studies. Representative images of PC3MS cells (upper panel) and LL/2R cells
(lower panels) show a 3D reconstruction of at least 20 slices. Phalloidin (F-actin) is shown in
red, Hoeschst nuclear stain is shown in blue. Scale bars represent 10 µm. R, resistant; S,
sensitive.
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HCT116R. In addition to faster growth rates in vivo and in vitro, resistant cells were significantly
smaller in diameter than sensitive cells, which may allow increased access to invade the
extracellular space, either through more efficient extravasation or secondary site colonization.
Faster growth and smaller size may be enough to render resistant cells too aggressive for buffer
therapy to be effective.
Further exploration, however, has revealed a number of other important molecular and
metabolic parameters that could contribute to resistance. Kinetic invasion assays suggest that
there are distinct mechanisms used for invasion by these two groups. Sensitive line invasion is
pH-dependent, allowing buffer therapy to intercept metastasis by neutralizing acidity in vivo.
Resistant cell line invasion, on the other hand, is pH-independent, bypassing the need for
acidosis to metastasize.
Metabolic alterations contribute to acidification of tumor microenvironments. Metabolic
profiling showed that sensitive cells were unequivocally more glycolytic than the resistant cells.
Cells with elevated glycolysis produce more acidic tumors. Previously, we have confirmed that
buffer therapy is an effective method of increasing the pHe of tumors, which diminishes the
ability of sensitive, but not resistant cells, to invade locally and metastasize [259,261,334]. While
resistant tumors were less acidic than highly glycolytic sensitive tumors, they were nonetheless
more acidic relative to normal tissues, likely due to poor perfusion. Neutralizing the tumor
acidity in these tumors had less of an effect on their metastatic potential because they have
upregulated mechanisms to bypass the need for acid-stimulated invasion. Expression, release,
and enzymatic activity of proteases are regulated by acidosis. While sensitive cells, PC3MS,
have measureable expression of MMPs, resistant cells, LL/2R, have consistently higher
expression of MMPs regardless of pH. Expression of MMPs correlated with protease activity in-

64

vivo. Interestingly, LL/2R tumors had a significant increase in MMP activity in response to
treatment, suggesting buffer therapy could exacerbate the metastatic burden, although increases
in metastatic formation in mice receiving buffer therapy was not observed. Protease activation in
resistant tumors is not adversely affected by buffer therapy, and allows resistant lines to
circumvent inhibition of metastasis by buffer therapy. Similar results were observed in a parallel
study [335], in which acidic pHe increased pericellular active cysteine cathepsins in vitro, which
was reduced following buffer therapy treatment in vivo (Figure 3.1). Furthermore, resistant and
sensitive cells exhibited distinct morphological differences in 3D culture systems. Interestingly,
acidic conditions resulted in the loss of protrusions in 3D culture of PC3MS, which may
contribute to their increased invasiveness in acidosis. Resistant and sensitive cells consistently
had differential responses to changes in extracellular pH, regardless of the inclusion or absence
of Matrigel matrix (migration, invasion and morphology studies), suggesting that the changes
observed were due to pH alterations, rather than cell signaling pathways such as integrin
signaling.
Although buffer therapy is not universally effective in reducing metastases, it does have
potential advantages over targeted cytotoxic chemotherapies that are in current clinical practice.
Tumors are heterogeneous, containing genetically distinct regional sub-populations that originate
over a lifetime of tumor growth [9,10,336]. Intrinsic or acquired resistance to chemotherapy is a
major obstacle of targeted therapies clinically, and will continue to remain so for the foreseeable
future [12]. In contrast, treatment of solid tumors with buffer therapy targets tumor acidity, a
common phenotypic consequence of tumor somatic evolution [27,337]. In addition to enhancing
local invasion and metastatic potential, tumor acidosis contributes to drug resistance through iontrapping of weakly basic chemotherapeutics, preventing active drug from reaching therapeutic
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doses within cells [25,258,260]. Therefore, buffer therapy may also be useful as an adjuvant to
traditional chemotherapies. Notably, a clinical trial of buffer therapy in cancer patients has
recently been initiated (NCT01846429).
In the current studies, buffer therapy was initiated prior to inoculation to prevent
progression to metastatic disease. Previous studies show buffer therapy has little effect on
reducing primary tumor growth, but significantly reduces spontaneous metastasis formation
[259]. Similarly, in a transgenic prostate cancer model, buffer therapy prevented development of
prostate adenocarcinoma when therapy was initiated immediately following weaning (4 weeks of
age) [262]. Interestingly, if therapy was initiated later (10 weeks of age) development of
prostate cancer was delayed, but was not inhibited, while progression to metastatic disease was
still prevented with treatment. Our data shows that buffer therapy is an effective method of
halting tumor progression and metastasis formation, but also indicates that the timing of therapy
initiation is instrumental for maximal efficacy. Future studies on optimization of buffer therapy
delivery and treatment schedules are necessary to harness the full potential of buffer therapy
clinically.
Identifying distinct metastatic mechanisms of sensitive and resistant tumors allows for
the identification of predictive biomarkers of buffer therapy response. FDG-PET screening may
be an ideal method of screening patients to assess their glycolytic phenotype to predict response
to buffer therapy. Clinically, FDG-PET imaging is used to diagnose up to 90% of primary
tumors, indicating that the vast majority of patients have glycolytic tumors that may benefit from
treatment with buffer therapy [338]. Further screening of additional cell lines for responsiveness
to buffer therapy will help solidify potential biomarkers or alternative treatments for resistant
tumors. A current limitation of our research was the use of five cell lines originating from
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different cancers. Deeper analysis into panels of cell lines originating from the same primary
organ site will surely provide more insight and will need to be studied in the future. Such
observations are commencing with the identification of two populations of HCT116 cells that
have distinctly different metabolic and invasive behaviors.
Materials and Methods
Animals
Animals were housed according to IACUC protocol at the USF Vivarium within Moffitt
Cancer Center. 4-6 week old SCID-beige (Charles River) or nu/nu mice (Harlan) were used in
experimental metastasis models or for fluorescent imaging of subcutaneous tumors, respectively.
Cell lines
PC-3M-Luc6 clone, B16-F10-G5 clone and LL/2-M38 clone luciferase expressing cells
were obtained from Xenogen Caliper. MDA-MB-231 and HCT116 cells (ATCC) stably
expressing luciferase were generated using lentiviral transduction. Cells were cultured in typical
incubation conditions (37°C and 5% CO2). Cell counts and diameters were measured with the
Countess Automated Cell Counter (Invitrogen).
Experimental Metastasis Model and Bioluminescent Imaging
Experimental metastasis models and bioluminescent imaging was performed as described
previously [334]. SCID-beige mice were pretreated with 200 mM Lysine or tap water for one
week prior to injection, and continued throughout the study. 1 x 106 cells were injected
intravenously in 100 µL PBS. Mice were imaged immediately after injection by bioluminescent
imaging to confirm successful injections. Metastasis formation is inferred from bioluminescent
signal, which is reported as mean log photons emitted/second ± SEM. MDA-MB-231 growth
rate doubling times (DT) were determined by fitting three parameter Gompertz function
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[339,340]. Statistical significance using Log-DT as a descriptor for the groups was determined
using one-sided Anova test.
Metabolic Profile Analysis
Metabolic profiles were determined using the Seahorse Extracellular Flux (XF-96)
analyzer (Seahorse Bioscience) as described previously [334]. Briefly, assay media was
supplemented with 11 mM glucose, 0.5 mM sodium pyruvate and 2 mM glutamine for
mitochondrial stress tests (MST) and glucose free media for glycolysis stress tests (GST). Cells
were treated with 1 µM oligomycin, FCCP, Rotenone and Antimycin during MST. GST
treatments include 11 mM glucose, 1 uM oligomycin and 100 mM 2DG. ECAR and OCR
values were standardized to mg/protein and reported as the mean ± SD.
Electrode measurement of tumor pH
pH measurements were performed as described previously [261]. Briefly, a reference
electrode was placed in a non-tumor site. A needle microelectrode (OD 0.8 mm with a beveled
end) was inserted into the center of the tumor, and was held in place until readings stabilized.
pH was measured at three locations and reported as mean ± SEM.
In-vivo protease activity measurements
nu/nu mice were provided with either tap water or 200mM free base lysine seven days
prior to inoculation (Sigma Aldrich). 1 x 106 LL/2 and PC3M cells were injected as bilateral
subcutaneous flank injections in PBS solution. 24 hours prior to imaging, mice were injected
with activatable fluorescent probes, MMPsense680 and Prosense750EX (Perkin Elmer),
intravenously. In-vivo measurements were obtained using the FMT2500 (Perkin Elmer)
tomographic imaging system. Fluorescent signal from each probe was quantified based on an
internal standard. Data was reported as mean ± SD.
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Quantitative PCR
RNA was isolated from cell pellets using RNeasy Mini Kit (Qiagen). qPCR reactions
were carried out with iScript One-Step RT-PCR kit with SYBR Green (Bio-Rad) using Applied
Biosystems StepOne PCR system (Applied Biosystem). MMP-2 and MMP-9 primers were
obtained from S. Chellepan (Moffitt Cancer Center)(Supplemental Table 1). Data was analyzed
using ΔΔCt, with the gene of interest normalized to β-actin.
Invasion Assay: Cells were pre-labeled with 10 µg/ml of DilC12(3) (BD Biosciences) before
seeding cells in serum free media into the apical chambers of the BD BioCoat™ Tumor Invasion
System (BD Biosciences). Media containing serum was used as a chemo-attractant in the basal
chambers. Fluorescence readings were obtained every 6 hours using BioTek Synergy HT plate
reader (BioTek Instruments).
Microscopy Studies
Cell migration assays were conducted using a 96-well plate WoundMaker™ (Essen
BioScience) to create homogenous 700-800 µm wounds. Images were recorded every 30
minutes and wound properties, including % Relative Wound Density (%RWD, shown below),
were measured with IncuCyte Software (Essen BioScience).
%RWD(t) = 100 x [w(t) - w(0)]/ [c(t) – c(0)]; where w(t) = Density of wound region at time, t;
and c(t) = Density of cell region at time, t.
Migration videos were recorded with a JuLi microscope using a 10x objective lens (NanoEnTek)
and generated with ImageJ software. Cell morphology studies were performed as previously
described [330]. Confocal images were obtained with an Olympus FV1000 MPE multiphoton
laser scanning microscope through a 60x LUM Plan FI/IR 0.9N.A. water immersion lens
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(Olympus). 405 diode and Red HeNe lasers were used to excite the samples. Images were
prepared using FV10-ASW Version 03.00.01.15 software (Olympus).
Data Analysis
Data was analyzed using GraphPad Prism v6.02 (GraphPad Software, Inc.) & Matlab
(MathWorks, Inc.). Statistics were performed using an unpaired two-tailed student’s t-test with
Welch’s correction. Data is reported as mean ±SD or ±SEM.
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CHAPTER 4
EVALUATION OF COMBINATION THERAPY AND POTENTIAL PREDICTIVE
BIOMARKERS FOR HYPOXIA ACTIVATED PRODRUGS IN PANCREATIC
CANCER

Note to Reader
Portions of this chapter have been previously published in Advances in Pharmacology,
2012, 65:63-107 [34] and are utilized with permission of the publisher.

Introduction
Tumor Hypoxia
Tumor hypoxia is found in solid tumors of all cancer types. As tumors outgrow their
vasculature, the diffusion limit of oxygen from a blood vessel (~200 µm) becomes a limiting
factor, resulting in insufficient oxygen and nutrient delivery to the tumor tissue. Angiogenesis,
one of the hallmarks of cancer [28,29], is initiated upon detection of hypoxia, but often generates
immature and chaotic vasculature in the tumor [272,341]. Disorganized and immature
vasculature results in tumor hypoxia that is extremely heterogeneous both temporally and
spatially. Diffusion-limiting hypoxia occurs in regions with mature, patent vasculature, but lack
well organized capillary beds to supply all regions of the tumor tissue. Perfusion-related hypoxia
occurs from inconsistent tumor blood flow within a tumor, resulting in regions of low
oxygenation [20]. Hypoxia is a potent selection force on cancer cells, contributing to tumor
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heterogeneity and propagating cancer phenotypes such as pro-survival [66,342] and altered
metabolism [343]. Hypoxia inhibits DNA damage repair pathways [22] and increases reactive
oxygen species (ROS) [344] resulting in genomic instability and promoting tumor progression
[345].
Tumor hypoxia is an indicator of poor prognosis in patients [346-348]. Reduced tumor
oxygenation, whether measured using oxygen electrodes, upregulation of hypoxia markers or
exogenous markers of hypoxia, consistently correlates with reduced overall survival in patients
[349]. Tumor hypoxia, in addition to selecting for a more aggressive cancer phenotype,
contributes to chemotherapy and radiation therapy resistance [350,351]. Hypoxia-associated
chemotherapy resistance can be mediated by: a lack of drug delivery to the tumor due to poor
perfusion [350], hypoxia-induced resistance to apoptosis [352], and decreased cell proliferation
of the hypoxic cell fractions [353]. Poor perfusion in tumors decreases chemotherapy
penetration into tumors, reducing the effectiveness of treatment [354,355]. Radiation therapy
requires the presence of oxygen to generate DNA-damage inducing free radicals, extinguishing
the cytotoxic effect of treatment in areas of low oxygenation [352,356,357]. Additionally,
hypoxic cell signaling pathways, orchestrated by HIF1α, can promote survival during radiation
therapy [358-360].
Targeting Tumor Hypoxia
Significant efforts have focused on developing clinical agents to reduce hypoxia in
tumors or target cells residing in the hypoxic niche (reviewed in detail in Chapter 2). Recently,
efforts to target the hypoxic compartments of tumors therapeutically have been pursued, most
notably through the use of hypoxia-activated prodrugs (HAPs). HAPs are relatively inert in
tissues with normal oxygenation (pO2), but are reduced by select one-electron oxidoreductases
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under hypoxic conditions to release cytotoxic or cytostatic effectors. A second generation HAP,
TH-302 is assembled on a 2-nitroimidazole hypoxia-sensitive trigger and is selectively activated
under extreme hypoxia (< 0.05% O2) to release a cytotoxic warhead, bromo-isophosphoramide
(Br-IPM) [120]. Similar 2-nitroimazoles, such as pimonidazole [361] and EF5 [362], are
routinely used in vivo to identify regions of tumor hypoxia through immunohistochemistry, but
lack the cytotoxic warhead of TH-302. TH-302 cytotoxicity has been evaluated extensively in
vitro [124] and is highly effective in preclinical mouse models [121,363]. Under hypoxic
conditions, TH-302 undergoes 1e- reduction mediated by CYPOR, releasing Br-IPM [124]. BrIPM, an alkylating agent, induces DNA damage and cell-cycle arrest in hypoxic cells, and
exhibits a bystander effect by killing cells in adjacent normoxic tissues [124].
TH-302 is being investigated clinically for several cancers including pancreatic, sarcoma,
multiple myeloma, glioma, kidney, liver, and non-small cell lung cancers (Table 4.1). TH-302
has been studied extensively in pancreatic patients with metastatic or unresectable disease.
Recently, a phase I/II trial showed that TH-302, in combination with gemcitabine, significantly
increased progression-free survival by 2.4 months for pancreatic patients compared to patients
receiving gemcitabine alone (p = 0.008) [364]. TH-302 has since advanced to phase III clinical
trials, which are currently recruiting participants (NCT01746979). TH-302 has also progressed
to phase III clinical trials in metastatic or locally advanced unresectable soft tissue sarcoma
patients (NCT01440088).
Manipulating Tumor Hypoxia
As tumor hypoxia is required for TH-302 activity, and TH-302 exhibits a bystander effect by
killing cells in adjacent normoxic tissues [121], we hypothesize that TH-302 efficacy could be
improved by transiently increasing the hypoxic fraction in solid tumors. In silico models and
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Table 4.1 TH-302 Clinical Trials
Clinical Trial
Registry Number
NCT00495144
NCT00742963

C
C

Clinical
Phase
1/2
1/2

A

3

R

3

R
R

1/2
2

A

1/2

R
R
C
N
A
R
R
R

1/2
1
1
1
1
1
2
2

A

2

A

1/2

R

1

Cancer Type

Advanced Solid Tumors
+/- Doxorubicin in Advanced Soft Tissue Sarcoma
+/- Doxorubicin in Unresectable or Metastatic Soft
NCT01440088
Tissue Sarcoma
+ Gemcitabine in Untreated Unresecetable Pancreatic
NCT01746979
Adenocarcinoma
+/- Bortezomib in Multiple Myeloma
NCT01522872
Advanced Melanoma
NCT01864538
+/- Sunitinib in RCC, GIST and Pancreatic
NCT01381822
Neuroendocrine Tumors
+ Sorafenib in Unresectable Kidney or Liver Cancer
NCT01497444
Solid Tumors and Pancreatic Cancer (Japan)
NCT01833546
Advanced Leukemia
NCT01149915
+ Doxorubicin in Hepatocellular Carcinoma
NCT01721941
+ Pazopanib in Advanced Solid Tumors
NCT01485042
Cardiac Safety Study in Advanced Solid Tumors
NCT02020226
+/- Bevacizumab in High Grade Glioma
NCT01403610
+/- Pemetrexed in Non-squamous NSCLC
NCT02093962
+/- Gemcitabine in Previously Untreated Pancreatic
NCT01144455
Adenocarcinoma
+ Gemcitabine, Docetaxel OR Pemetrexed in Advanced
NCT00743379
Solid Tumors
+ Gemcitabine AND Nab-Paclitaxel in Previously
NCT02047500
Untreated Pancreatic Cancer
A = Active; C = Complete; R = Recruiting; N = Not yet recruiting

experimental evidence show the most effective approach to decrease tumor pO2 is to increase
cellular respiration [365]. This was effective in colon carcinoma cells (RKO) in which
pharmacological inhibition of HIF-1α with echinomycin increased oxygen consumption,
decreased tumor pO2 and increased the activity of the HAP, tirapazamine [366]. This treatment
resulted in a chronically hypoxic environment that could lead to further hypoxic adaptation of the
tumor cells and HAP side effects. In contrast, we propose that transient and acute exacerbation of
hypoxia, in combination with TH-302, would be more effective with fewer side-effects. Prior
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work has observed that exogeneous pyruvate increases the hypoxic fraction in squamous cell
carcinoma (SCC) tumors [136] through a transient increase in oxygen consumption (unpublished
observations). We have observed that exogenous pyruvate increased efficacy of TH-302 in preclinical SCC and PDAC models (unpublished observations and [367]). To explore alternative
pharmacologic methods to transiently exacerbate hypoxia and hence enhance the anti-tumor
properties of TH-302, we herein investigate the “Steal” phenomenon.
The “Steal” phenomenon has been extensively documented in cancer models [368]. The
“Steal” phenomenon occurs when vasodilators, such as hydralazine, cause health blood vessels
to dilate leading to decreased systemic blood pressure (Figure 4.1). Tumor vasculature is often
immature and atonal, lacking the ability to constrict or dilate. Hence, during systemic
vasodilation, there is a physiological reduction in blood pressure that cannot be matched by the
tumor microenvironment and vasculature. The resulting pressure difference creates a transient
decrease in tumor perfusion [369-371], increase in tumor hypoxia [372], and increase in tumor
acidosis [144,373-375]. Hydralazine has been shown to reduce tumor blood flow within 30
minutes and lasts for 4 to 6 hours [376]. Interestingly, low doses of hydralazine (0.1 mg/kg)
increase tumor blood flow, but higher doses (2.5 – 10.0 mg/kg) are effective to reduce tumor
perfusion by 80-90% [143]. Hydralazine has been used to enhance the activity of first generation
hypoxia-targeted chemotherapies [377,378] and hyperthermia [379,380] by increasing tumor
hypoxia , but has not been investigated using current HAPs, including TH-302. In this study we
hypothesized that hydralazine could be used acutely to reduce perfusion and increase hypoxia
within the tumor microenvironment, thus enhancing the efficacy of TH-302 in pancreatic tumor
models.
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Figure adapted from J. Wojtkowiak

Figure 4.1 The Steal Phenomenon. Treatment with hydralazine, a vasodilator, cause healthy
patent vasculature to dilate resulting in a systemic reduction in blood pressure. Tumor
vasculature is often immature and atonal, lacking the ability to constrict or dilate. During
systemic vasodilation, there is a physiological reduction in blood pressure that cannot be
matched by the tumor microenvironment and vasculature. The resulting pressure differents
creases a transient decrease in tumor perfusion, resulting in increased hypoxia. We hypothesize
that increased hypoxia following hydralazine treatment will expand the region of TH-302
activation, increasing TH-302 efficacy in pancreatic xenograft models.

Hypoxia in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) patients have extremely poor prognoses, with
a 5-year survival rate of approximately 6%. Survival remains low due to a lack of early
detection while PDAC is still localized and ineffectiveness of traditional chemotherapies to
control PDAC progression. These low survival rates demonstrate the need to develop novel
treatment strategies. Pathologically, PDAC tumors are extremely heterogeneous and contain a
dynamic desmoplastic stromal compartment, both of which contribute to tumor progression and
chemotherapy resistance [381,382]. Desmoplastic stroma is proliferative fibrotic tissue that
promotes tumor progression and metastasis [382]. In addition to being a mechanical barrier for
drug penetration, desmoplastic stroma contributes profoundly to tumor hypoxia; a common
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physiological trait of PDAC tumors that is also associated with both chemotherapy and
radiotherapy resistance [350,357,383]. Hypoxic tumor tissues have also been shown to have
increased metastatic potential [346] and a majority of PDAC tumors present as metastatic latestage disease.
Results
PDAC xenografts exhibit variable sensitivity to TH-302 in vitro and in vivo
Previous studies have shown variable response of three PDAC cell lines, Hs766t,
MiaPaCa-2 and SU.86.86, to TH-302 monotherapy both in vitro and in vivo. Treatment of cells
cultured under anoxic conditions with TH-302 show that MiaPaCa-2 cells are the most sensitive
(IC50 = 2.1 ± 0.7 µmol/L); SU.86.86 responding moderately (IC50 = 12 ± 1.2 µmol/L); and
Hs766t the least sensitive (IC50 = 60 ± 7.5 µmol/L) [124]. Interestingly in vivo, tumor xenograft
models using the same cell lines show different responses to TH-302 monotherapy. Hs766t
responded the most favorably to TH-302 treatment [121], with complete inhibition of tumor
growth, while MiaPaCa-2 tumors were moderately responsive [384] and SU.86.86 tumors were
resistant to TH-302 monotherapy [385]. The differential response of PDAC cells in vitro and in
vivo emphasizes the importance of the hypoxic fraction within a tumor for maximal TH-302
efficacy in vivo as SU.86.86 tumors are highly vascularized and well oxygenated, while Hs766t
tumors have large hypoxic fractions [363].
pH electrode results indicate that MiaPaCa-2 tumors exhibit “Steal”effect in response to
hydralazine
Since hydralazine treatment has previously been shown to reduce tumor blood flow in
vivo [370], we hypothesized that hydralazine could be used to transiently increase the hypoxic
fraction in tumors and increase TH-302 efficacy. Hydralazine has also been shown to increase
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tumor acidosis [144], which may be an effective method to identify tumors exhibiting a “Steal”
effect that would be more responsive to combination therapy. To test our hypothesis, mice
bearing subcutaneous SU.86.86, MiaPaCa-2 or Hs766t tumors were anesthetized and tumor pH
was measured using a pH microelectrode (performed by Heather H. Cornnell). To measure pH
changes resulting from blood flow changes, mice were administered 10 mg/kg hydralazine via
intraperitoneal (ip) injection. Tumor pH measurements were obtained every 30 minutes
following hydralazine treatment for three hours. We hypothesized that tumors exhibiting the
“Steal” effect will experience tumor acidification following hydralazine treatment. The TH-302
sensitive Hs766t tumors (n = 3) exhibited no change in average pH following treatment with
hydralazine (Figure 4.2). TH-302 resistant SU.86.86 tumors (n = 7), however, experience a
paradoxical small increase in pH (+ 0.05 pH units) following treatment with hydralazine (Figure
4.2). MiaPaCa-2 tumors (n = 4), which are moderately responsive to TH-302, consistently
exhibited a “Steal” effect following hydralazine treatment, experiencing a significant reduction
in pH (- 0.12 pH units) relative to SU.86.86 (p < 0.007) and Hs766t (p < 0.05) (Figure 4.2).
Though heterogeneity existed between tumor samples, each sample tested responded similarly to
the other tumors within their cohorts, as evidenced by observing the single animal maximum
change, the average of the maximal response from each animal during the experiment and the
average change in pH for each animal for each time point measured (Figure 4.2). These results
indicate that administration of hydralazine led to decreased perfusion in MiaPaCa-2 tumors, but
did not affect perfusion in either Hs766t or SU.86.86 tumors.
Hydralazine treatment results in a reduction in tumor blood flow within 15 minutes
To further explore the effects of hydralazine on tumors that exhibited the “Steal” effect, used
Doppler ultrasound was used to measure the tumor blood flow following hydralazine treatment
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Figure 4.2 pH electrode results indicate that MiaPaCa-2 tumors exhibit “Steal” Effect in
response to hydralazine. Mice bearing subcutaneous SU.86.86 (n = 7), Hs766t (n = 3) or
MiaPaCa-2 (n = 4) flank tumors were anesthetized and tumor pH measurements were obtained.
A reference electrode was inserted under the skin of the mouse in a non-tumor site while the pH
electrode was inserted up to 1.3 cm into the center of each tumor. Two measurements were
taken at each time point and averaged. Following initial pH measurements, mice were
administered 10 mg/kg hydralazine via ip injection. Tumor pH was measured for 3 hours
following treatment. Data reported represents the average maximum change in each cohort, the
average pH change for each cohort and the single animal maximum pH change for each cohort.
Data is reported as mean change in pH ± SEM. *p < 0.05; **p <0.007.

in MiaPaCa-2 tumors. Prior to hydralazine treatment, color Doppler images were obtained
across MiaPaCa-2 tumors (n = 4) to identify major tumor vasculature (Figure 4.3, left panel).
Using a pulsed wave (PW) Doppler, blood flow through tumor vasculature was measured over
30 minutes following hydralazine ip administration (Figure 4.3, right panel). A reduction in
blood flow was observed within 15 minutes of hydralazine injection (Figure 4.3, right panel).
Quantification of these data confirmed a reduction in tumor blood flow beginning 15 minutes
after hydralazine injection with a continued decline through 30 minutes (Figure 4.4).

79

Figure 4.3 Hydralazine treatment results in reduction in tumor blood flow. Mice bearing
MiaPaCa-2 tumors were analyzed by Doppler ultrasound to quantify tumor blood flow. (Left
Panel) Tumors were scanned using color Doppler imaging to identify major tumor vasculature
prior to treatment. Red represents blood flow through tumor vasculature. White arrow marks
vasculature chosen for analysis. (Right Panel) Following hydralazine administration, pulsed
wave (PW) Doppler was used every 5 minutes for 30 minutes to quantify blood flow following
hydralazine treatment.

MiaPaCa-2 tumors lack tonal mature vasculature
Tumor samples from each cell line were analyzed histologically to characterize the
vasculature. CD31 and smooth muscle actin (SMA) are two common tumor vasculature
immunohistochemistry (IHC) markers that identify the presence (CD31), and the maturity and
tone (SMA) of vasculature. Tumors with significant vasculature that are tonal would not be
expected to exhibit the “Steal” phenomenon, as the tumor vasculature would dilate in
coordination with the systemic effects of hydralazine treatment. Using positive pixel analysis,
we quantified the percentage of Hs766t, SU.86.86 and MiaPaCa-2 tumors that contained CD31
and SMA staining. Consistent with the prior results, SU.86.86 tumors had significantly more
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Figure 4.4 Hydralazine treatment results in a reduction in tumor blood flow within 15 minutes.
Mice bearing MiaPaCa-2 tumors were analyzed by Doppler ultrasound to quantify tumor blood
flow. Quantification of tumor blood flow changes in MiaPaCa-2 tumors (n = 4) following
hydralazine treatment. Data is reported as mean velocity (mm/sec) ± SEM.

CD31 (p < 0.05) staining than either Hs766t or MiaPaCa-2 (Figure 4.5A-B), and significantly
more SMA (p < 0.005) than MiaPaCa-2 tumor samples (Figure 4.5A, C). These data indicate
that SU.86.86 tumors are well vascularized with mature vessels that would be expected to dilate
in response to hydralazine treatment. MiaPaCa-2 and Hs766t tumors had similar amounts of
CD31 staining (Figure 4.5A-B). MiaPaCa-2 tumors had the least amount of SMA staining
among the three tumors tested (Figure 4.5A, C). These data indicate that MiaPaCa-2
vasculature is immature and atonal. As MiaPaCa-2 tumors displayed decreased tumor blood
flow (Figure 4.3 and 4.4) and a subsequent decrease in tumor pH (Figure 4.2), we conclude that
MiaPaCa-2 tumors exhibit the “Steal” effect due to immature tumor vasculature.
Vasculature markers identify “Steal” responsive melanoma tumors
Two melanoma tumor xenograft models were also studied for their response to the
“Steal” phenomenon following treatment with hydralazine. pH electrode measurements show
that 1205Lu xenografts experience a reduction in pH following hydralazine treatment, which is
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consistent with “Steal” responsive tumors (Figure 4.6A). MDAMB435 tumors, however, do not
exhibit the “Steal” effect in response to hydralazine treatment, maintaining their pH throughout
the course of the experiment (Figure 4.6A). Tumor samples were analyzed for vasculature
markers, CD31 and SMA, using immunohistochemistry to confirm the biomarker patterns
observed in pancreatic tumors (Figure 4.5). Consistent with vasculature staining in pancreatic
tumors, positive pixel analysis of CD31 staining shows that “Steal” responsive tumors, 1205Lu,
have significantly less tumor vasculature (p < 0.01) than “Steal” resistant tumors, MDAMB435
(Figure 4.6B). SMA staining analysis shows a similar trend, that “Steal” responsive tumors
have less mature vasculature than “Steal” resistant tumors (Figure 4.6C). These data indicate
that tumor vasculature markers are an effective biomarker to identify tumors that exhibit the
“Steal” effect in response to vasodilator treatment.
MiaPaCa-2 tumors are moderately sensitive to TH-302, and the effect is slightly
enhanced with hydralazine
To test TH-302 monotherapy and combination therapy with hydralazine for each cell line
xenograft, mice were implanted with subcutaneous Hs766t, SU.86.86 or MiaPaCa-2 flank
tumors, and pair-matched into four cohorts: untreated (saline), TH-302 alone (50 mg/kg ip),
hydralazine alone (10 mg/kg ip) and TH-302/hydralazine combination therapy. In combination
therapy, TH-302 was administered 30 minutes following hydralazine administration as this
appeared to be the time of maximal effect on perfusion post-hydralazine. All cohorts were
treated for two cycles of 5 consecutive treatments followed by 2 days off, and tumor volumes
were monitored with electronic calipers during the course of the study. As anticipated, Hs766t
tumor growth was completely inhibited with TH-302 monotherapy (Figure 4.7), SU.86.86 tumor
growth was unaffected by TH-302 monotherapy (Figure 4.8) and MiaPaCa-2 tumors responded
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Figure 4.5 MiaPaCa-2 tumors lack tonal mature vasculature. Hs766t, MiaPaCa-2 and SU.86.86
tumors were fixed and embedded in paraffin in preparation for IHC staining for tumor
vasculature markers, CD31 and SMA. (A) Representative images of tumors stained with CD31
and SMA. Scale bars represent 100 µm. Positive pixel analysis of (B) CD31 and (C) SMA
staining across the whole area of a tumor. Data is presented as % Positivity [(positive
pixels/total pixels) x 100] ± SEM. *p < 0.05; **p < 0.005.

moderately to treatment (Figure 4.9). Combination therapy of hydralazine followed by
administration of TH-302 had no beneficial effect on tumor volume control in mice bearing
Hs766t or SU.86.86 tumors relative to cohorts treated with TH-302 monotherapy (Figures 4.7
and 4.8). Importantly, neither of these tumor models exhibited the “Steal” effect following
hydralazine administration (Figure 4.2). MiaPaCa-2 tumors respond moderately to TH-302
monotherapy (Figure 4.9) and experienced an increase in tumor acidosis due to reduced tumor
blood flow following hydralazine treatment (Figure 4.2). Mice bearing MiaPaCa-2 tumors
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Figure 4.6 Vasculature markers identify “Steal” responsive melanoma tumors. (A) Mice bearing
subcutaneous 1205Lu (n = 2) and MDAMB435(n = 2) melanoma tumors were anesthetized and
tumor pH measurements were obtained following 10 mg/kg hydralazine treatment. Data is
presented as the average ± SEM. 1205Lu and MDAMB435 tumors were fixed and embedded in
paraffin in preparation for IHC staining for vasculature markers, CD31 and SMA. Positive pixel
analysis of (B) CD31 and (C) SMA staining across the whole area of the tumor. Data is
presented as % Positivity [(positive pixels/total pixels) x 100] ± SD. **p < 0.01

Figure 4.7 Hs766t tumors are sensitive to TH-302, and the effect is not enhanced with
hydralazine. Mice bearing subcutaneous Hs766t tumors (n = 9 per cohort) were pair-matched
into 4 cohorts: saline control, TH-302 alone, hydralazine alone, and TH-302 + hydralazine. TH302 (50mg/kg ip) was administered 30 minutes after hydralazine (10 mg/kg ip) in the
combination therapy cohort. (A) Hs766t tumor volumes and (B) Kaplain-Meier curve showing
time until tumor volumes reach 1000 mm3. Tumor volumes are presented as mean tumor volume
± SEM. ↑ = dose administered.
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experienced a modest further reduction in tumor volume growth when treated with TH302/hydralazine combinationtherapy compared to TH-302 monotherapy (Figure 4.9). Despite a
trending reduction in tumor growth between TH-302/hydralazine combination therapy and TH302 monotherapy, statistical analyses of the growth curves indicate that the differences did not
achieve statistical significance (p < 0.08). This experiment was repeated a total of three times,
once by myself, with similar results (data not shown). In all cases, MiaPaCa-2 tumors treated
with combination therapy had reduced growth, but it was not significantly lower (p = 0.07) than
that of the TH-302 monotherapy group.
Combination therapy dosing regimen optimization increases TH-302 efficacy in
MiaPaCa-2 tumors
The regimen for combination therapy above included hydralazine treatment 30 minutes prior to
TH-302 administration. However, it is possible that the reduced blood flow at 30 minutes also
prevented delivery of TH-302 to the tumor, thus reducing prodrug penetration and activation.
Hence, we investigated if an alternate combination dosing regimen would enhance TH-302
efficacy. In a subsequent set of experiments, TH-302 and hydralazine was administered
simultaneously to maximize the amount of time TH-302 was exposed to hypoxia due to reduced
tumor blood flow. Mice bearing MiaPaCa-2 tumors were pair-matched into three cohorts: TH302 monotherapy, administration of TH-302 30 minutes after hydralazine, and simultaneous
administration of TH-302 and hydralazine. Drug treatments were administered in the same doses
as previously described, and were given for two cycles of 5 consecutive days followed by 2 days
off. As before, TH-302 treatment 30 minutes post hydralazine trended towards reducing tumor
volume growth compared to TH-302 monotherapy, though again the results did not reach
statistical significance (p = 0.08) (Figure 4.10). Interestingly, administration of TH-302 and
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Figure 4.8 SU.86.86 tumors are resistant to TH-302, and the effect is not enhanced with
hydralazine. Mice bearing subcutaneous SU.86.86 tumors (n = 9 per cohort) were pair-matched
into 4 cohorts: saline control, TH-302 alone, hydralazine alone, and TH-302 + hydralazine. TH302 (50mg/kg ip) was administered 30 minutes after hydralazine (10 mg/kg ip) in the
combination therapy cohort. (A) SU.86.86 tumor volumes and (B) Kaplain-Meier curve
showing time until tumor volumes reach 1000 mm3. Tumor volumes are presented as mean
tumor volume ± SEM. ↑ = dose administered.

hydralazine simultaneously resulted in better tumor volume control and was significantly better
than TH-302 monotherapy (p < 0.05) immediately following the completion of the treatment
regimen (day 18) (Figure 4.10). While simultaneous combination therapy did increase TH-302
efficacy, long term tumor volume control was not achieved after therapy was completed.
Discussion
Drugs targeting or activated by the physiological tumor microenvironment have the
potential to increase antitumor efficacy while reducing side effects from non-specific toxicities.
One such class of drug, hypoxia activated prodrugs (HAP), are relatively inert under
physiological pO2 levels in normal tissues, but are activated in areas of hypoxia, which is a
common characteristic of solid tumors [28,29]. TH-302, a HAP that is built upon a 2nitroimidazole scaffold, has been successful in the treatment of pre-clinical models [121,124]
and is currently being investigated in clinical trials. Though in phase III trials to treat pancreatic
patients in combination with gemcitabine (NCT01746979), long-term control of pancreatic
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Figure 4.9 MiaPaCa-2 tumors are moderately sensitive to TH-302, and the effect is slightly
enhanced with hydralazine. Mice bearing subcutaneous MiaPaCa-2 tumors were pair-matched
into 4 cohorts: saline control (n = 10), TH-302 alone (n = 9), hydralazine alone (n = 7), and TH302 + hydralazine (n = 7). TH-302 (50mg/kg ip) was administered 30 minutes after hydralazine
(10 mg/kg ip) in the combination therapy cohort. (A) MiaPaCa-2 tumor volumes and (B)
Kaplain-Meier curve showing time until tumor volumes reach 1000 mm3. Tumor volumes are
presented as mean tumor volume ± SEM. ↑ = dose administered.

patients in combination with gemcitabine (NCT01746979), long-term control of pancreatic
cancer progression has yet to be achieved. We hypothesize that TH-302 activity can be
increased in vivo by transiently increasing hypoxia within tumors. The use of anti-angiogenic
agents, such as vascular endothelial growth factor receptor (VEGFR) inhibitor sunitinib, have
been investigated, but the effect on tumor hypoxia varies depending upon the model and regimen
employed [386]. We have previously demonstrated that TH-302 efficacy can be exacerbated in
pre-clinical pancreatic tumor models by transiently increasing tumor hypoxic fraction
metabolically with bolus pyruvate administration (unpublished observations).
In this study, we aimed to determine if the hypoxic fraction of pancreatic tumors could be
increased with vasodilators to improve TH-302 efficacy. Hydralazine, a vasodilator used
clinically to treat hypertension, has been shown previously to reduce tumor blood flow through
the “Steal” phenomenon [370]. By measuring the change in pH in pancreatic tumor models
following hydralazine treatment, we were able to identify tumors that exhibit the “Steal” effect in
vivo. MiaPaCa-2 tumors experienced a significant drop in pH following treatment with
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Figure 4.10 Combination therapy dosing regimen optimization increases TH-302 efficacy in
MiaPaCa-2 tumors. Mice bearing MiaPaCa-2 tumors were pair-matched into 3 cohorts (n = 10
per cohort): TH-302 monotherapy, TH-302 30 minutes after hydralazine, and simultaneous
administration of TH-302 and hydralazine. TH-302 (50 mg/kg) and hydralazine (10 mg/kg)
were administered ip, and treatment consisted of 2 cycles of 5 continuous treatments with 2 days
off. (A) Tumor volume measurements of MiaPaCa-2 tumors. (B) Kaplan-Meier curve showing
time until MiaPaCa-2 tumors reached 1000 mm3. Tumor volumes are presented as mean tumor
volume ± SEM. *p < 0.05; ↑ = dose administered.

hydralazine, which is associated with reduced blood flow through the tumor, and these effects
were consistent with reduced blood flow, measured by Doppler ultrasound. Neither SU.86.86
nor Hs766t tumors exhibited the “Steal” effect in vivo following hydralazine treatment. There
was no change in pH in Hs766t or SU.86.86 tumors, possibly due to the presence of mature
patent vasculature. Staining of histology sections for smooth muscle actin, SMA, and CD31 was
a negative predictor of response to hydralazine in both pancreatic and melanoma tumor models.
As the maximal reduction in blood flow following hydralazine treatment was 30 minutes,
we designed the treatment regimen to dose TH-302 30 minutes after hydralazine to maximize the
exposure to increased hypoxia. Mice bearing Hs766t and SU.86.86 tumors saw no benefit to
combination therapy of hydralazine and TH-302 compared to TH-302 monotherapy, in
accordance with the lack of a “Steal” effect observed above. In three separate experiments, mice
bearing MiaPaCa-2 tumors, experienced a consistent and modest (p = 0.07) reduction in tumor
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growth with combination hydralazine and TH-302 therapy compared to TH-302 monotherapy.
Further, the therapeutic effect was identical whether hydralazine and TH-302 were given
sequentially or simultaneously. Interestingly, studies have been performed to study the
effectiveness of topical vasodilators to initiate the “Steal” response over repeated treatments.
Abramovic et al. demonstrated that the magnitude of hypoxia and the duration of response
following vasodilator treatment decreased with each subsequent dose, leading to a reduction in
efficacy over time [387]. The treatment schedule used in this study required 5 consecutive days
of treatment, which may have resulted in a reduction in the “Steal” response of MiaPaCa-2
tumors by the end of each treatment cycle. The lack of significant long-term control of
MiaPaCa-2 pancreatic tumors with combination therapy and the possibility that hydralazine
therapy may become ineffective after multiple treatment cycles indicate that vasodilators will
likely not be used clinically to enhance HAP efficacy. However, the study served as a proof of
concept that tumor hypoxia can be modulated to improve the efficacy of HAPs.
Materials and Methods
Cell Culture
SU.86.86 and Hs766t cells were obtained from Threshold Pharmaceuticals (South San
Francisco, CA) and MiaPaCa-2 cells were obtained from American Type Cell Collection
(ATCC, Manassas, VA). Cells were maintained in accordance with ATCC guidelines. Cells
were incubated in RPMI 1640 supplemented with 10% FBS (Hs766t and SU.86.86) or DMEM
supplemented with 10% FBS (MiaPaCa-2), and were maintained at 37° C in 5% CO2.
Mycoplasma and cell line authenticity (karyotype) tests were performed.
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Animal Studies
All animals were cared for in compliance with Institutional Animal Care and Use
Committee (IACUC) approved protocols, and housed at either the USF Vivarium within Moffitt
Cancer Center or within the Arizona Cancer Center facility. SCID-beige female mice (Harlan
Laboratories, Indianapolis, IN) were inoculated with 5 – 10 x 106 cells in 1:1 Matrigel (BD
Biosciences, Franklin Lakes, NJ): PBS solution subcutaneously on the right flank. Tumor
growth was monitored biweekly with electronic calipers throughout the duration of the
experiments.
pH Electrode
pH measurements were obtained using an FE20 Five Easy pH meter (Mettler-Toledo,
Columbus, OH). All animals were sedated with isoflurane (3.5%), and remained under
anesthesia (1.5 – 3.5% isoflurane) for the duration of the experiment. A reference and pH
electrode (MI-401F and MI-408B, respectively, Microelectrodes Inc., Bedford, NH) were used to
measure the pH by first inserting the reference electrode (OD 1mm) under the skin of the mouse
near the tumor (flank). The pH electrode (OD 0.8mm) was then inserted up to 1.3 cm into the
center of each subcutaneous tumor. Electrodes were calibrated prior to and following each set of
measurements. Two measurements were taken at each time point and averaged. After the initial
pH measurements, the animals were administered 100 µL intraperitoneal (ip) injection of 10
mg/kg hydralazine (Sigma Aldrich, St. Louis, MO). The pH was measured every 30 minutes up
to three hours after ip injection, and care was taken to measure the pH in approximately the same
place in the tumor at each time point. After the final pH measurement, animals were sacrificed
and tumors were harvested for histology. Data were processed by taking the average of the two
pH values measured at each time point. The change in pH, or delta (Δ(t), where t is the time

90

after injection of hydralazine or saline, in minutes) was measured as the difference between the
first time point pH and each subsequent time point pH. For each tumor type, the average delta
(AvgΔ) is the average delta for all animals of that tumor type:
t

Avg 


A

 (t )

30180

nt
nA

Where t is time, which ranges from 30 to 180 minutes after injection, A is the animal, nt is the
number time points measured, and nA is the number of animals with that tumor type. The
maximum change in pH at any time after injection was identified for each individual animal.
The average maximum across each tumor type was calculated, and the largest change for any one
animal in each group was also identified. The number of animals measured varied per tumor
type: Hs 766T, n=3; MIA PaCa-2 n=4; and SU.86.86, n=7.
Ultrasound Imaging
Ultrasound imaging was performed on the Vevo2100 with the 22-55 MHz transducer
MS550D (Visual Sonics, Toronto, Ontario, Canada). Mice bearing MiaPaCa-2 tumors (n = 4)
were sedated (as described above) through the duration of imaging. Color Doppler images were
taken to establish the location of a major blood vessel within the tumor. Once a sufficiently large
blood vessel was located, a pulsed wave (PW) Doppler was taken for quantification of flow. The
animal received a 100 µL injection of 10 mg/kg hydralazine, and the flow in the same blood
vessel was remeasured every 5 minutes for 30 minutes.
Drug Regimens and Tumor Growth Kinetics Monitoring
Animals were pair matched by tumor volume (as calculated by electronic calipers) when
tumors reached ~200 mm3. Animals were separated into four drug treatment groups (n = 9
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animals per treatment group for Hs 766T and SU.86.86, numbers listed for MiaPaCa-2): i) TH302 (n = 9), ii) Hydralazine (n = 7), iii) TH-302 + Hydralazine (n = 7) and iv) Saline (control, n
= 10). The treatments were administered as ip injections to un-anesthetized animals. The doses
were 50 mg/kg TH-302 in 200 L saline for each animal in groups i and iii, 10 mg/kg
hydralazine in 100 L saline per animal [144] in groups ii and iii, and 200 L saline for group iv.
Group iii received hydralazine 30 minutes before the administration of TH-302. During
simultaneous dosing of hydralazine and TH-302, hydralazine was injected ip immediately before
TH-302. All treatment plans were administered Q5D for two concurrent weeks. The tumor
volumes were measured twice a week using electronic calipers for the duration of the
experiment.
Tissue Processing and Immunohistochemistry
At the completion of the in vivo studies, animals were euthanized and tumors were
excised. Tumors were fixed in formalin and embedded in paraffin for further processing.
Staining for hematoxylin and eosin (H&E) was performed on 4 µm slices.
Immunohistochemical (IHC) staining was completed at the Moffitt Tissue Core using Res IHC
Omni0UltraMap HRP XT Discovery XT Staining Module (Ventana Medical Systems Inc.). IHC
analysis was completed for CD31 (Abcam ab28364) and Smooth Muscle Actin [SMA (Abcam
ab32575)]. Slides were scanned with the Aperio™ ScanScope XT (Vista, CA), and positive
pixel analysis was performed using Aperio Genie® v1 software. Briefly, the algorithm measured
staining intensity across the entire area of the tumor and classified the number of pixels
containing stained tissue. The results are presented as percent positivity, which was calculated as
the number of positive pixels divided by the total number of pixels multiplied by 100.
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Data Analysis
Data were analyzed using GraphPad Prism v6.02 (GraphPad Software Inc.). Statistics
were performed using an unpaired 2-tailed Student’s t test with Welch’s correction. Data are
reported as mean ± SEM.
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CHAPTER 5
CONCLUSION

Cancer prevalence is increasing annually in the United States, and is the second most
common disease behind heart disease. Approximately 14 million Americans are living with the
disease, and unfortunately over half a million people will die from cancer this year [388]. Ninety
percent of these cancer related deaths are attributed to metastatic disease [294]. The field of
cancer research is exploding with valuable novel understanding of such a complex disease.
Improved techniques with incredible sensitivity have allowed us to form new fields to
understand cancer from every angle: genomics, proteomics, metabolomics, radiomics, etc.
Despite the influx of knowledge, we are still struggling to control the disease. Cancer prevention
and early detection methods have revolutionized the field [389], but for most patients, cancer is
not detected until a sizable tumor is found or the patient develops side effects.
Molecular biology in particular has transformed cancer research and clinical practices.
Mutated oncogenes and tumor suppressors have been identified and key oncogenic signaling
pathways have been described. Drug discovery efforts have yielded many therapies that are
specifically targeted to inhibit mutated proteins, halting oncogenic cell signaling pathways and
killing cancer cells. Despite developing excellent drugs, these targeted therapies are only
efficacious temporarily with tumors ultimately becoming resistant to therapy [12]. Due to
inherent heterogeneity within a tumor, resistant populations (whether innate or acquired) will
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emerge upon selection with a targeted therapy [9,10,336]. The inevitable emergence of
resistance indicates an urgent need to develop novel methods to treat cancer in patients.
Targeting the tumor microenvironment, however, focuses on targeting phenotypic
characteristics of tumors rather than genotypic, reducing the likelihood for the development of
resistance. Two phenotypic characteristics of the tumor microenvironment are hypoxia and
acidosis and occur in nearly every solid tumor. Hypoxia occurs due to chaotic and immature
tumor vasculature, and can be transiently and spatially heterogeneous within a tumor [20]. Lack
of oxygen promotes metabolism of glucose through glycolysis, which eventually becomes a
fixed trait of solid tumors regardless of the oxygenation status [23,283]. Aerobic glycolysis, or
the Warburg Effect, generates significant lactic acid waste product, which is then shuttled into
the tumor microenvironment to maintain proper intracellular pH. Lactic acid waste builds up in
the tumor microenvironment, unable to be removed by inadequate tumor vasculature, resulting in
acidosis [15,16]. Both hypoxia and acidosis contribute significantly to tumor progression,
malignancy and chemoresistance [26,216,217].
Efforts to target the tumor microenvironment have been made in earnest, some of which
have been more successful than others. Inhibitors have been generated for many enzymatic steps
of glycolysis, from glucose transporters to lactate dehydrogenase inhibitors. Interestingly, one 2hexokinase inhibitor, 2-DG, has had a transformative effect on cancer imaging, much more so
than its effectiveness to kill tumor cells.

18

F-2DG is used to diagnose and stage up to 90% of

tumors and identify sites of metastatic dissemination [338], illustrating the universal importance
of the glycolytic pathway in cancer. Targeting acidosis with systemic buffers has been proven to
be an effective method to prevent cancer progression and metastatic dissemination in murine
models. Ingestion of buffers, such as sodium bicarbonate, imidazoles, TRIS and lysine, increase
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the buffering capacity of blood through the alkaline tide phenomenon [259,261,334]. Tumor
acidosis is selectively targeted and buffered following treatment with orally available buffers,
increasing the pH of the tumor microenvironment. When buffer therapy treatment is initiated
prior to tumor development, cancer progression is successfully inhibited in a transgenic prostate
cancer model [262]. Once a tumor has formed, however, buffer therapy is ineffective in
controlling tumor growth, but importantly is effective in preventing progression to metastatic
disease, which is the lethal stage in cancer.
Unfortunately, buffer therapy is not universally effective. Chapter 3 focuses on
identifying mechanisms of buffer therapy resistance, where we effectively showed that cell lines
that are sensitive to buffer therapy treatment use a pH-dependent mechanism for metastatic
dissemination [279]. Buffer therapy sensitive tumors are more acidic than buffer therapy
resistant tumors, which is supported by a significantly higher glycolytic flux. Acidic culture
conditions alter cellular morphology and migration patterns of buffer therapy sensitive cells,
which ultimately contributed to increased invasion. Treatment with buffer therapy effectively
increases the pH in sensitive tumors, preventing acid-mediated changes in cellular morphology
and migration and preventing invasion. Buffer therapy resistant cells, however, use a pHindependent mechanism for metastatic dissemination, rendering them unresponsive to buffer
therapy treatment. Buffer therapy resistant cells constitutively express proteases and maintained
protease activity, even during treatment with buffers. By identifying mechanisms of buffer
resistance, we can focus on identifying biomarkers that will predict sensitivity to buffer therapy
treatment. As 18F-2DG is commonly used clinically, we will study its effectiveness to
differentiate tumors that will be responsive to buffer therapy versus tumors that will be
unresponsive to buffer therapy.
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Chapter 4 focused on another method of manipulating the tumor microenvironment for
therapeutic benefit. Hypoxia is a major contributor to tumor development, malignancy and
resistance to therapy [22]. Cellular response pathways to hypoxia have long been a target of
drug discover and many drugs have been clinically investigated and approved by the FDA
(Table 2.1). Hypoxia activated prodrugs (HAPs) target cells residing in hypoxic niches by
selective activation by hypoxia. One such compound, TH-302, is activated in regions of extreme
hypoxia (< 0.05% O2) and is being investigated clinically in many cancers, including pancreatic
cancer (Table 4.1) [120,121,124,363]. In Chapter 4, a method to increase hypoxia transiently in
pancreatic tumors using a vasodilator, hydralazine, to increase TH-302 efficacy was investigated.
Treatment with hydralazine causes a systemic reduction in blood pressure that cannot be
matched by the tumor vasculature, which is unresponsive to vasodilators. Pressure differences
between systemic vasculature and tumor vasculature creates a sink, pulling or “stealing” blood
from a tumor, ultimately resulting in a transient increase in hypoxia [370]. Hydralazine
treatment reduces blood flow in a pancreatic tumor model, exacerbating acidosis in tumors that
exhibited the “steal” effect. Measuring tumor pH and using vasculature markers CD31 and
smooth muscle actin (SMA) were predictive of tumors that exhibit the “steal” effect and were
responsive to hydralazine and TH-302 combination therapy. While hydralazine marginally
increased TH-302 efficacy in our pancreatic model and did not achieve long term control, this
study served as proof-of-concept that the tumor microenvironment can effectively manipulated
to enhance therapeutic efficacy.
While targeting the tumor microenvironment lessens the likelihood for the development
of resistance, the emergence of resistant populations following therapy is still a potential clinical
issue. The presence of inherently resistant populations for both methods of targeting the tumor
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microenvironment in this dissertation suggests that tumoral heterogeneity may limit the efficacy
of therapies targeting the tumor microenvironment. Identification of biomarkers that can
effectively predict response to either buffer therapy or treatment with hypoxia activated prodrugs
will be essential to maximize clinical efficacy. Additionally, more research is needed to
understand the potential for the development of resistance to therapies that target the tumor
microenvironment. There is evidence for the development of resistance to buffer therapy, as
metastases begin to form after several weeks of therapy (Figures 3.3 and 3.6). Efforts to study
the metastasis that form in mice that are receiving buffer therapy are being conducted to identify
additional mechanisms of resistance that can arise during the course of therapy. As our
understanding of resistance to microenvironmental therapies increases, we can better tailor
therapeutic regimens and use combinations of targeted therapies and therapies targeting the
tumor microenvironment to achieve better clinical outcomes.
As we become more knowledgeable about the development and progression of cancer, it
is ever more imperative to take a step back and consider the “big picture” of cancer evolution.
Bombarding patients with high dose targeted therapy has shown time and time again to lead
directly to drug resistance. Understanding the evolutionary selection forces that result from drug
treatment and learning how to harness the drugs we currently have available by using adaptive
therapy will help to alleviate drug resistance. Finally, identifying novel therapies and optimize
existing therapies that target the tumor microenvironment will ultimately lead to better cancer
prevention and tumor control practices clinically.
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